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In recent years, the fields of regenerative medicine and developmental biology have been
revolutionized by the ability to reprogram adult somatic cells back to a pluripotent state, producing
induced pluripotent stem cells (iPSCs) through the induction of the reprogramming factors OCT4, SOX2,
KLF4 and c-MYC (OSKM). The promise of this technique has been somewhat limited by the low
efficiency and long duration of the process which produces heterogeneous mixtures of cells in culture,
many of which fail to fully reprogram over a 3-4 week period. Research in recent years has focused on the
underlying mechanisms of reprogramming and identifying rate-limiting steps in the process. Most studies
to date utilize bulk measurements of cells undergoing reprogramming however, these techniques cannot
measure the changes occurring in rare cells that will become iPSCs and are inherently biased towards
unsuccessful reprogramming events. Here we apply single cell technologies to measure the dynamics of
mRNA and protein expression and develop mathematical models to precisely describe these behaviors.
We find that productively reprogramming cells activate genes in an ordered, probabilistic fashion but do
so independently of one another, lacking hallmarks of gene regulatory network activity. Some genes,
despite their expression as mRNAs, are not immediately translated into protein, identifying posttranscriptional mechanisms as a potential rate limiting step. In contrast, cells moving along an alternate
trajectory away from fibroblast but not towards iPSC, fail to activate pluripotency genes and do not
express the full complement of OSKM. This is due to premature inactivation of the individual factors,
causing cells to drop off the productive trajectory and fail to reprogram. Performing these analyses under
two different delivery methods of OSKM and in two cell types reveals that while the timing of gene
activation varies between conditions, the probabilistic order of gene activation is conserved, suggesting a
common reprogramming trajectory. Taken together these findings represent the first descriptions of
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mRNA and protein expression dynamics in single, human cells undergoing reprogramming. We also
provide a robust mathematical framework for identifying rate-limiting steps in the process and dissecting
the mechanism of action of treatments known to enhance the efficiency of reprogramming.
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Chapter 1 Introduction
1.1 Project Context and Significance
A pluripotent, embryonic stem cell (ESC) cell is defined by its ability to differentiate into all
three embryonic germ layers (endoderm, mesoderm and ectoderm) and can thus contribute to all cell
types of an adult organism1. In 2005 Takahashi et al demonstrated that overexpression of the transcription
factors OCT4, SOX2, KLF4 and c-MYC (OSKM) could revert differentiated somatic cells to a
pluripotent state 2. This process of somatic cell reprogramming generates induced Pluripotent Stem Cells
(iPSCs), which promise to revolutionize the field of regenerative medicine. While this technique was
developed nearly a decade ago, many barriers still exist to the efficient and reproducible derivation of
iPSCs by this method 3–5. At the time this project was initiated much of the focus in the reprogramming
field was on developing different methods to improve the efficiency of the process by manipulating the
delivery method of OSKM and introducing new factors or small molecules to the cocktail 6,7. These
efforts yielded small increases in efficiency and provided some insight into the barriers to successful
reprogramming, however little was known about the molecular changes occurring during the transition
from the somatic to pluripotent state. Early efforts aimed at studying the process itself relied on bulk
measurements of cells undergoing reprogramming and were performed primarily in mouse 8–11. Because
reprogramming is temporally asynchronous and produces considerable cellular heterogeneity 11–14, these
approaches are not optimal for understanding this process in detail. In addition, many variables contribute
to the overall rate and efficiency of reprogramming including the species and cell type of the starting
population, as well as the method used to initiate the process.
For these reasons, the goal of this project is to use single cell genomic and proteomic
technologies to profile individual cells at the transcript and protein level as they are driven from a somatic
to a pluripotent state in human cells. Since the initiation of the project six years ago, the field has
advanced at a dizzying pace and other single-cell resolution studies of the process have been reported.
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However, this work represents the first single cell analysis of mRNA and protein expression in human
reprogramming and the first to compare the dynamics of the process under different reprogramming
conditions. This methodology provides novel insights into how human cells acquire pluripotent
characteristics, a necessary step for the therapeutic implementation of the technique. In addition, the
statistical methods utilized herein contribute to the nascent field of single-cell data analysis and provide a
framework for deconstructing complex biological populations that can be extended to a variety of
systems.

1.2 The Epigenetic Landscape
During normal development, pluripotent cells with the ability to generate all tissues of the
organism progressively lose their developmental potential as they differentiate into increasingly
specialized cell types 10,15–18. Known as canalization, this process was first articulated in 1948 by Conrad
Waddington rapidly becoming a dogma of developmental biology. He likened the developmental
potential of a cell to a ball rolling down a hill. Just as a ball loses potential energy as it reaches the base of
the hill, so too does a cell lose developmental potential as it differentiates into increasingly specialized
cell types. This epigenetic landscape as he called it, becomes more restrictive as development proceeds,
inactivating regions of the genome and thus canalizing the developmental potential of the cell. It is this
epigenetic restriction that produces stable cell types and prevents their spontaneous reversion to a more
primitive developmental state. Conversely, reprograming to pluripotency represents a reversal of
developmental potential, akin to rolling the ball back up the hill. This process requires a strong external
force to perturb a cell from its stable somatic state followed by a suite of molecular changes including
resetting of the epigenetic landscape that must occur en route to pluripotency 4,8,19,20.

1.3 Methods of Reprogramming
Reprogramming was first demonstrated using Somatic Cell Nuclear Transfer (SCNT) to generate
pluripotent cells by transferring the nucleus of a differentiated cell type into an enucleated oocyte 21.
SCNT remains the most rapid and efficient method of generating pluripotent cells in vitro and has been
2

widely used to clone animals from a variety of species 22–26. This method was recently demonstrated to
work in human cells 27 however, it remains highly controversial and requires an abundance of oocyte
donors in order to be feasible for therapeutic purposes.
In 2005, Takahashi et al used retroviruses to overexpress the transcription factors OCT4, SOX2,
KLF4 and c-MYC (OSKM) to reprogram skin fibroblasts to pluripotency at an efficiency of 0.01% over a
period of 30 days 2,28. This finding was heralded as a boon for regenerative medicine, promising to
provide patient-derived stem cells for therapeutic purposes while avoiding the ethical concerns of SCNT.
Because retroviruses containing the 4 factors integrate randomly and may induce unintended alterations to
the host genome, they are not ideal for use in therapeutic applications 29,30. To address this issue, methods
have been developed to reprogram cells using floxed OSKM cassettes or piggy-bac vectors to generate
“footprint-free” iPSCs 31–34, as well as non-integrating methods such as episomal vectors or mini-circle
constructs 31,35–37. Cells have also been reprogrammed by DNA-free approaches including mRNA/miRNA
transfection, protein transduction and recently, small molecule cocktails 38–42. In addition to altering the
delivery method of OSKM, other factor combinations have also been used to successfully reprogram
cells. In particular, the Thompson cocktail of OCT4, SOX2, NANOG and LIN28 has been particularly
effective and has been shown to act synergistically with OSKM, suggesting these factors promote
reprogramming by distinct pathways 6.

1.4 Interrogating the Reprogramming Process
Great strides have been made in recent years to uncover the molecular changes occurring during
reprogramming however, our ability to interpret and synthesize these results into meaningful models is
complicated by three key features of the process. First, the low efficiency of reprogramming results in
1:1,000 – 1:10,000 cells being successfully reprogrammed. Second, infection with OSKM produces
considerable cellular heterogeneity as evidenced by the variety of stable, partially reprogrammed
intermediates that can be isolated at various stages of the process and the transcriptional and epigenetic
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variation observed in fully reprogrammed iPSCs 2,9,43–48. Lastly, reprogramming is temporally
asynchronous with cells responding to OSKM and progressing towards pluripotency at different rates 11.
The majority of the studies to date rely on the analysis of bulk populations of reprogramming
cells and thus are inherently biased towards measuring events that do not lead to pluripotency. In addition
the asynchrony and heterogeneity of the process results in bulk expression profiles that reflect an
averaging of a continuum of cell states, rather than a discrete population. Despite these complications,
population-level measurements have shed light on the ensemble protein and mRNA expression changes
during reprogramming and provide insight into the major molecular changes required to achieve
pluripotency. Understanding the events occurring in the minority of cells that become iPSCs however,
requires techniques with resolution at the single-cell level.
The first single-cell technology used to interrogate the reprogramming process was time-lapse
microscopy, whereby cells infected with OSKM were recorded over time and monitored for changes in
cell morphology, cell cycle rate and the expression of reporter genes linked to successful reprogramming
49

. In particular, Nanog-GFP and Oct4-GFP reporters have been commonly used to monitor the

endogenous activation of these key pluripotency loci, events that have been shown to occur late in the
process 11,12,50,51. Retroactive tracing of these reporter-positive populations back to their initial infection
with OSKM has revealed a stepwise progression of cells through the reprogramming process,
characterized by an early increase in cell-cycle rate and decrease in cell size, followed by a mesenchymal
to epithelial transition and lastly, the activation of the GFP reporter construct 51–55. The fact that these
events occur in a reproducible order suggests that reprogramming is an ordered process, however the
molecular resolution of this technique is limited and cannot interrogate mRNA and protein-level changes
with appreciable throughput.
The advent of single-cell genomics and proteomics solutions has allowed genome/proteome-wide
profiling of individual cells undergoing reprogramming. While this thesis project was being completed,
single-cell mRNA profiling was performed in both mouse and human cells utilizing FACS to enrich for
4

individual productive reprogramming events followed by qPCR or mRNA-seq 56,57. Recently, single cell
proteomics methodologies such as CyTOF, which allows the simultaneous analysis of up to 40 proteins in
1 X 105 – 1 X 106 individual cells has been applied to mouse reprogramming, adding an additional level
of resolution to our understanding of the process 58,59. The specific findings and models derived from
these studies are elaborated below.

1.5 Molecular Dynamics during Reprogramming to Pluripotency
Reprogramming to pluripotency requires an exquisite coordination of molecular/cellular events to
revert a “terminally” differentiated somatic cell back to an embryonic pluripotent state, a feat equivalent
to developmental time-travel. These alterations in cell state encompass every biological process
imaginable, from mRNA, protein, miRNA and non-coding RNA expression, to epigenetics, metabolism
and morphology. What follows is an attempt to summarize the vast array of knowledge accumulated to
date about these processes but which is likely to evolve rapidly as the field continues to progress at an
astonishing rate.

1.5.1

Epigenetics

Perhaps the greatest rate-limiting step to successful reprogramming is the resetting of the
epigenetic landscape from a somatic to a pluripotent state. This includes DNA methylation and histone
modifications which can control the expression of individual loci and thus, most if not all molecular
changes occurring during reprogramming (mRNA, miRNA, lncRNA, protein etc.) first require a change
in epigenetic state. These changes are not merely a consequence of reprogramming, but can directly
influence the course of reprogramming as well. This is evidenced by the effects of small molecule
chromatin modifiers and altered expression of chromatin-modifying enzymes on the efficiency of the
process. In general, molecules/factors that promote open chromatin structure such as the HDAC inhibitors
valproic acid (VPA) and trichostatin A (TSA) or over-expression of the trithorax subunit WDR5
(involved in H3K4me3) improve efficiency 60–62, while interventions that reinforce repressive chromatin
like knockdown of the H3K9 demethylase LSD1, reduce efficiency 63,64. In addition to these generalized
5

observations, much is known about the specific chromatin state changes taking place during
reprogramming as well.
Almost as soon as reprogramming factor expression is initiated, a plethora of epigenetic
modifying enzymes are upregulated, including histone methyltransferases, histone
deacetylases/acetyltransferases and nucleosome remodeling complexes65. Early in reprogramming,
somatic genes that will eventually become silenced lose the activating H3K4me3 mark and gradually
acquire repressive H3K27me3 8,66. The converse happens at loci activated during the process, particularly
genes that are peripheral to the “core” pluripotency network, where H3K27me3 is lost in favor of
H3K4me3. Often, these changes occur first in the enhancer regions, followed by changes at the promotor
of the corresponding loci 67. Later in reprogramming (around day 10 in mouse), H3K9me3 and DNA
methylation changes occur. These modifications are typically associated with long-term silencing of
genes and are commonly found among the core pluripotency factors including OCT4, SOX2, NANOG
and others 68,69. While it is unclear how DNA methylation is removed during reprogramming, it is
thought to occur through both active and passive means; passively through the dilution of the
modification by DNA replication without maintenance of the methylation mark and actively through the
expression of the Tet and Aid demethylation enzymes 70,71. Loss of DNA methylation at core pluripotency
loci by either means is a key late-step in reprogramming, as evidenced by the conversion of stable,
partially reprogrammed cells to pluripotency after treatment with the DNA methylation inhibitor 5-azacytidine 9,61. In conjunction with the aforementioned epigenetic changes, a subset of loci, mostly
transcription factors involved in development, acquire a bivalent chromatin state characterized by cooccupancy of active H3K4me3 and repressive H3K27me3. This occurs gradually over the course of
reprogramming and the dynamics of this change is poorly understood 72,73.

1.5.2

Transcription

Transcriptional changes occurring early in reprogramming are governed by the binding of the
OSKM transcription factors to DNA as dictated by the epigenetic landscape. An early wave of gene
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induction is associated with promoter regions decorated with the activating histone mark H3K4me3 and
the binding of c-MYC and KLF4 67,74. This includes a set of “early pluripotency” genes as well as loci
associated with apoptosis. Indeed, apoptosis is a common end-point for many reprogramming cells and
knockdown of p53 by shRNA has been used to increase reprogramming efficiency 31,75,76. Simultaneously,
late pluripotency loci that possess repressive epigenetic marks such as H3K27me3 and DNA methylation
in somatic cells, are bound by a combination of O, S, K and/or M at their distal enhancer regions but
remain transcriptionally inactive at this stage. During the second wave of transcriptional activity a
concomitant loss of H3K27me3 and DNA methylation and gain of H3K4me3 occurs at genes that will
become active in the pluripotent state (i.e. late pluripotency genes). At this stage, the expression of
pluripotency loci is governed by combinations of transcription factors similar but not identical to those
observed in true hESCs/iPSCs.
While the above primarily refers to changes in mRNA expression, miRNA and lncRNA
expression have also been measured during the course of reprogramming 40,41,77–80. The expression of
miRNAs exhibits a biphasic pattern similar to that of mRNA expression, with miRNAs targeting
fibroblast genes induced early and those targeting pluripotency genes down-regulated late in the process.
This results in the expected inverse correlation between the expression of miRNAs and their
corresponding mRNA targets. For example, miR-294 is upregulated early in reprogramming and its target
TGFBR2 is subsequently downregulated as cells reprogram39,78,81. The opposite is true for the let-7
miRNA which is turned off late in reprogramming, allowing the pluripotency loci LIN28 and SALL4 to
be activated in the iPSC state82. Similarly, the expression of lncRNAs have recently been shown to shift
from a fibroblast to pluripotent expression profile 83. lncRNAs recruit epigenetic modifying complexes to
target loci and thus play an important role in establishing the epigenetic landscape and stabilizing cellular
identity. Taken together, the dynamics of mRNA, miRNA and lncRNA expression demonstrate the
concerted transcriptional changes that must occur as cells transition to a pluripotent state, each of which
represents a potential barrier to successful reprogramming.
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1.5.3

Protein Expression

In bulk samples subjected to LC/MS-MS, protein expression dynamics reflect what is seen at the
mRNA level, with an early wave of activation associated with MYC target loci and a late wave of
pluripotency gene activation 84,85. Interestingly, by comparing these data with bulk mRNA-seq
measurements collected in parallel, these authors also find that genes involved in cell adhesion,
androgen/oestrogen signaling and mitochondrial function have a lower correlation at the protein
compared with the mRNA level. These findings were extended by Hansson et. al. who demonstrated
mRNA and protein expression exhibit greater correlation early in reprogramming and that this
relationship deteriorates later in the process. Together, this suggests that post-transcriptional regulation of
protein expression may be a rate limiting step in the reprogramming process, however it is unclear if this
phenomenon occurs in the few cells undergoing productive reprogramming which would require singlecell resolution to establish definitively.
Recently, mass cytometry (CyTOF) has emerged as a technology to profile protein expression in
individual cells using a combination of flow cytometry and mass spectrometry which can measure ~40
proteins in hundreds of thousands of individual cells86. This technique was recently used to profile mouse
fibroblasts undergoing reprogramming for a panel of 34 proteins58,59. While these studies did not report
waves of expression as indicated by bulk analysis, they did identify apparent intermediate states on the
route to pluripotency. This includes an early OCT4highKLF4high population that later activates CD73 and
CD104 and finally EpCAM before acquiring an iPSC-like profile. This late activation of EpCAM, a
marker of MET is in contrast to previous reports at the mRNA level that MET is an early event in the
process. Again, the discordance between mRNA and protein expression suggest post-transcriptional
regulation may play an important role in the reprogramming process. In addition to the above-mentioned
trajectory, these authors also identify a subset of reprogramming cells that exit the cell cycle (as
evidenced by low Ki67 expression) and altogether fail to productively reprogram. Most importantly, these
studies have identified a unique intermediate CD73+, CD49d+, CD200+ population of cells, of which 12%
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become iPSCs. This represents the greatest enrichment for productive reprogramming intermediates to
date and demonstrates the power of CyTOF to identify useful biomarkers in highly heterogeneous
populations of cells. Furthermore, CyTOF can interrogate post transcriptional modifications such as
phosphorylation and methylation of histones and other proteins, permitting single cell analysis of entirely
new levels of cellular activity such as epigenetics and the kineome.

1.5.4

Cell Cycle

Human fibroblasts (and many other somatic cell types) exhibit doubling times on the order of 2436hrs whereas ESCs double once every 16-18hrs53,87–89. This represents a challenge for reprogramming
cells to increase their progression through the cell cycle and proliferate more rapidly. It is thought that a
major role of c-MYC in the OSKM cocktail is to increase proliferation of cells and while reprogramming
can succeed in its absence, the efficiency is ~100-fold lower 32,74,90. Not only is an increase in cell cycle
progression critical for the maintenance of pluripotency, it is also thought to facilitate changes in the
epigenetic landscape 11,91; the replication of the genome represents an opportunity to dilute somatic
epigenetic modifications while marks associated with pluripotency are established on the newly
synthesized DNA. This is corroborated by a report from Hanna et al., whose modeling of the
reprogramming process showed that the number of cell divisions is a better predictor of successful
reprogramming than days post OSKM induction11.

1.5.5

Mesenchymal to Epithelial Transition

Many cell types used for reprogramming including fibroblasts are mesenchymal in nature,
making limited cell-to-cell contacts and producing extra cellular matrix components to facilitate adhesion
to and mobility across surfaces. These cells also express characteristic mesenchymal genes including NCadherin, Vimentin, Fibronectin, Snai2 and Twist, the maintenance of which is dependent on TGFB
signaling54,92,93. In contrast, embryonic stem cells form an epithelium with tight cell-to-cell junctions and
form colonies in culture with basal-apical polarity, an activity primarily coordinated by the expression of
E-Cadherin and EpCAM94,95. Reprogramming cells must undergo a mesenchymal to epithelial transition
9

(EMT), a critical step in the conversion to pluripotency, but there are conflicting reports as to whether this
is an early or late event in the process55,58,96.

1.5.6

Inactivation of OSKM Viruses

For reprogramming methods that rely on viral delivery of OSKM, inactivation of the four factors
is a critical late step in forming iPSCs4,97. The persistence of OSKM expression is associated with the
generation of non-iPSC, self-renewing cell types in reprogramming cultures as well as aberrant
differentiation of iPSCs into target cell types33,98–100. This is due to the sensitivity of ESCs and iPSCs to
transcription factor dosage which control the balance between pluripotency and differentiation101–103. For
example, persistent OCT4 expression prevents the differentiation of iPSCs, while as little as 2.5-fold
overexpression of SOX2 downregulates pluripotency targets and promotes differentiation to neuronal and
mesodermal lineages104–106. While the importance of inactivating OSKM in iPSCs is well understood, the
mechanisms by which this occurs are not. It has been found that silenced retroviral elements in ESCs are
associated with H3K9me3 and DNA methylation and binding of the MeCP2 and HP1 proteins in the viral
LTRs. However, none of the known mediators of these modifications are specifically expressed in cell
types where silencing occurs and thus the factors involved in this process have yet to be identified97,107–109.

1.6 Models of the Reprogramming Process
Through the extensive molecular data generated in recent years, a model of the reprogramming
process has emerged. The variety of datasets (mRNA vs protein, single-cell vs bulk, etc.) somewhat
complicates a unified model, however several common themes have been observed. In 2013, Buganim et
al proposed a two-phased model of reprogramming following single cell mRNA analysis in the mouse
system. They observed that cells responding to OSKM infection initially transition through a “stochastic
phase,” whereby gene expression patterns appear random and uncoordinated. This is followed by a
“deterministic phase” with cells activating key pluripotency loci in a stepwise, hierarchical fashion56,110.
While the deterministic phase is thought to occur rapidly as cells become locked into a pluripotent fate,
the stochastic phase is protracted and probabilistic, resulting in the asynchrony or “variable latency” that
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is characteristic of the process. This is concordant with the observations that the binding of the OSKM
factors early in reprogramming (48hrs post-infection) is dictated by the epigenetic state of the target loci
and that changes in the epigenetic state is required for factor binding to some loci, in particular
pluripotency genes with repressive chromatin states67. Remodeling of the epigenetic landscape is
facilitated by DNA replication and cell division and thus increased in cell cycle have been shown to
improve reprogramming efficiency. Consistent with this notion, factors that increase cell proliferation and
promote permissive chromatin states (ie histone acetylation) also improve the efficiency of
reprogramming111.
The deterministic phase was identified by comparing the expression profiles of single-cells late in
the reprogramming process that had not activated an Oct4-GFP reporter, with Oct4-GFP+ reprogramming
cells. Bayesian analysis of these populations revealed a hierarchy of pluripotency gene activation initiated
by the expression of Sox2. Successful reprogramming, albeit at a lower efficiency, was observed by
overexpression of downstream members in this cascade in the absence of Sox2, further corroborating
these findings.
Taken together, this model implicates the stochastic phase as the major rate limiting step in
reprogramming and provides a target for improving the rate and efficiency of the process. In contrast,
dissection of the hierarchical phase is likely to provide informative biomarkers that can be used to identify
successful reprogramming events. This model, while supported by data from human reprogramming
experiments is largely comprised of studies performed in mouse and it is unclear how these findings
translate between the two species.

1.7 Mouse vs Human
The therapeutic potential of reprogramming is dependent on our ability to understand and
optimize the technique in human cells. Despite this fact, the overwhelming majority of research into the
mechanisms and dynamics of the process comes from studies in mouse due to the abundance of genetic
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tools available to manipulate these cells and the increased speed of reprogramming in this system112–114.
Reprogramming in mouse occurs in as little as 10 days, compared with 30 days in human cells and the
efficiency can be up to 20-fold higher in mouse91. In addition, many studies of reprogramming in mouse
take advantage of secondary reprogramming systems whereby mouse fibroblasts are infected with a
doxycycline-inducible OSKM construct, reprogrammed to iPSCs and subsequently re-differentiated into
fibroblasts. Addition of doxycycline to these cultures allows for a more homogeneous reprogramming
process and facilitates molecular dissection of the events leading to pluripotency. It is unclear however,
whether the prior reprogramming of these cells faithfully represents the process as it occurs in primary
fibroblasts. Thus, much of what we know about the molecular underpinnings of reprogramming come
from artificial mouse systems and it is unclear how these finding translate to human cells. While it is
expected that the cellular processes involved will be consistent between species, the particular genes
implicated in these processes may be different. Indeed, the wiring of the gene regulatory networks
governing early development are quite varied between the two species115. Nonetheless, much of the
information to date comes from mouse reprogramming, illustrating the need for similarly detailed studies
to be performed in human cells.

1.8 Scope of the Thesis
The primary goal of this thesis is to profile the transcript and protein dynamics in human cells
undergoing reprogramming by OSKM at single-cell resolution and to model progression of cells through
the stochastic phase. After establishing a baseline model, this analysis is performed under two delivery
methods of the OSKM virus (monocistronic and polycistronic) and in two different cell types (BJ and
MRC-5 fibroblasts) to better understand how differences in reprogramming conditions impact the
acquisition of pluripotency.
Because much of our current knowledge of reprogramming comes from transgenic mouse
systems and a variety of reprogramming methods, it remains to be seen how these findings translate to the
human reprogramming system and whether the method of reprogramming has an impact on the process.
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By examining both mRNA expression dynamics under different reprogramming conditions as well as
protein expression, this work provides a unified model of the reprogramming process that is directly
relevant to the therapeutic application of the technique. In addition, the statistical models developed
herein provide powerful tools for the field of single-cell analysis to dissect and interrogate heterogeneous
mixtures of cells.

Chapter 2

Single Cell Analysis and Modeling of Monocistronic Reprogramming
by OSKM
This work was published in PLOS ONE in 2014

2.1 Introduction
Methods of reprograming somatic cells to a pluripotent state (iPSC) have enabled the
direct modeling of human disease and ultimately promise to revolutionize regenerative medicine
5,116

. While iPSCs can be consistently generated through viral infection with the Yamanaka

Factors OCT4, SOX2, KLF4, and c-MYC (OSKM) 2, infected cells rapidly become
heterogeneous with significant differences in transcriptional and epigenetic profiles, as well as
developmental potential 14,46,117–119. This heterogeneity, the low efficiency of iPSC generation
(0.1-0.01%) and the fact that many iPSC lines display karyotypic and phenotypic abnormalities
44,120,121

has hindered the production of iPSCs that can be used safely and reliably in a clinical

setting. A thorough mechanistic understanding of the reprogramming process is critical to
overcoming these barriers to the clinical use of iPSC.
In the past several years, ChIP-seq and RNA-Seq experiments have revealed ensemble
gene expression and epigenetic changes that occur during reprogramming by OSKM, and have
greatly enhanced our understanding of the process 5,10,50,66,122. These studies require the use of
populations of cells comprised of heterogeneous mixtures undergoing reprogramming (0.0113

0.1% of which will become iPSC) or stable, partially reprogrammed self-renewing lines arrested
in a partially reprogrammed state, unlikely to ever become iPSCs without additional
manipulation 14,117–119. Because these techniques rely on either the ensemble properties of mixed
populations, or upon the analysis of cell lines arrested at partially reprogrammed states that may
not be representative of normal intermediate steps in a functional reprogramming process, they
have limited ability to reveal the changes that appear to be essential to successful
reprogramming.
Longitudinal single-cell imaging studies provide a powerful complement to ensemble,
population level analyses. Live imaging studies have identified a number of key morphological
and cell cycle related changes that occur during reprogramming to iPSC 55,123. These
observations suggest that an ordered set of phenotypic changes precede acquisition of the fully
pluripotent state 10. However, these studies are necessarily limited in their molecular-genetic
resolution, and they provide little insight to the transcriptional changes accompanying key
morphological and developmental transitions in the reprogramming process.
Recently, a single-cell transcriptional analysis of reprogramming of mouse fibroblasts by
OSKM revealed that reprogramming proceeds in two major phases: an early stochastic phase
followed by a rapid “hierarchical” phase 110. While the latter phase appears deterministic and is
characterized by the coordinated expression of pluripotency genes in an ordered fashion, the
early phase exhibits apparently random gene expression patterns that persist through the majority
of the process 110,124. This conclusion is further supported by two key pieces of evidence from
other studies: 1) transgenic OSKM activity is required for the majority of the reprogramming
process, indicating that most of this process is not governed by the concerted action of the
endogenous pluripotency gene regulatory network (GRN) 51,52,123; and 2) a mechanistically
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undescribed period of variable ‘latency’ of cells in the stochastic phase results in significant
temporal variability in the appearance of fully reprogrammed iPSC colonies 11. Some insight to
pluripotency gene activation during the stochastic phase was provided by a recent study in mouse
fibroblasts that describes the ‘gradual activation of pluripotency genes’ between the initial
response to OSKM induction and the activation and stabilization of the pluripotency GRN 8.
Together, these findings suggest that the stochastic phase is a major rate-limiting step in the
reprogramming process, but provide little mechanistic insight into the molecular underpinnings
of these events. In addition, it has not yet been determined how these findings translate to the
reprogramming of human cells, which will be required prior to clinical application of iPSCs.
Several studies have attributed the protracted stochastic phase to the requirement for
extensive chromatin remodeling during reprogramming 21,125. These changes involve the
complex coordination of factors to deposit and remove histone modifications and DNA
methylation at specific loci to achieve a pluripotent epigenetic state. The need to reset the
epigenetic landscape appears to delay the coordinated activation of the pluripotency GRN and is
likely to be a major barrier to rapid and efficient reprogramming. Indeed, it has been shown that
OSKM binding in the early stages of reprogramming is greatly impeded by the presence of
repressive chromatin, and initial binding is largely restricted to existing open chromatin domains
5,50,66,67,69

. Subsequent remodeling of somatic cell chromatin clearly occurs, but the order and

mechanism of remodeling events during the stochastic phase is not fully understood. Accurate
mapping of gene expression dynamics during the stochastic phase can provide a framework for
the molecular dissection of these rate-limiting events in reprogramming.
In this study we perform single-cell transcript analysis of MRC-5 human lung fibroblasts
undergoing reprogramming by OSKM and find that cells appear to follow two trajectories: one
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toward an ESC-like state (the “productive” trajectory) and the other away from both ESC and
fibroblasts (the “alternative” trajectory). These trajectories can be differentiated by the concerted
consolidation of expression of a suite of chromatin modifiers in cells entering the productive
trajectory and the down-regulation of these same genes in cells entering the alternative trajectory.
By analyzing the dynamics of gene expression changes along the productive trajectory (toward
pluripotency) we demonstrate that changes in gene expression in the stochastic phase of
reprogramming are not simply gradual and random; rather, genes are activated and inactivated at
specific points during the progression from fibroblast to iPSC. Coupling single-cell transcript
profiling with mathematical modeling we show that the gradual acquisition of pluripotency gene
expression during reprogramming occurs as an ordered, probabilistic, gene-specific process that
shows no signatures of interdependence between genes. This finding is consistent with the
hypothesis that gene-specific chromatin states in the starting cells control gene activation
dynamics during the reprogramming process. Our map of reprogramming also provides a robust
model that can be used to dissect the precise mechanisms and chromatin modifications that limit
the rate and efficiency of conversion of somatic cells to iPSC. This work represents a rigorous
single cell transcript analysis of the reprogramming process in human cells and lays the
foundation for the precise measurement and mechanistic dissection of this critical rate-limiting
step in reprogramming.

2.2 Results
2.2.1

Experimental Design

In this report we combine qualitatively and quantitatively robust single-cell transcript
profiling 126 with FACS to measure the progression of individual MRC-5 human fetal lung
fibroblasts through the reprogramming process. To make our results as broadly relevant as
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possible we used viral delivery of the OSKM transgene cocktail, the most widespread method
applied to human cell reprogramming 28,127. At select time points after transduction, cells were
dissociated, stained, analyzed and collected by FACS. FACS markers used in this study include
GFP (virus derived), αSSEA4, αTRA-1-60, and αCDH1 (see Materials and Methods). These
markers were essential and allowed for enrichment of the rare cells exhibiting hallmarks of
productive reprogramming. For example, SSEA4 and TRA-1-60 routinely provide ~30 and 3,000
fold enrichment, respectively (data not shown). While very few SSEA4+ cells are likely to
become true iPSCs, they provide a measurement of cells that have begun to exit the fibroblast
state in response to OSKM transduction. In contrast, isolation of TRA-1-60+ cells later in
reprogramming (Day 14) is likely to yield a large number of cells destined to become iPSC. In
fact, >90% of these cells remain TRA-1-60+ after sorting and subsequent culture and this
stability of the TRA-1-60+ phenotype has been shown to be a major determinant for the potential
of cells to become iPSC 57. Single cells with defined FACS phenotypes were collected into cell
lysis buffer and subject to single-cell RT-qPCR as previously described 126 (Figure 1A and
Supplemental Figure 1). Throughout the course of this study we isolated and pre-screened 576
cells in total, using 172 cells that passed quality control for our final analysis (see Materials and
Methods and Supplemental Table 1). This includes many partially reprogrammed cells, as well
as an un-transduced set of MRC-5 fibroblasts and H9 human embryonic stem cells (H9-hESC),
which represent the beginning and end states of the process, respectively.
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In order to monitor progress toward pluripotency, and away from the fibroblast state, we
assembled a 48-gene qPCR panel including genes expressed in fibroblasts 55,128,129, a large
number of genes involved in the maintenance of pluripotency (including various chromatin
modifiers) 122,130–132 and genes previously suggested to be intermediate markers of the
reprogramming process 9,49. For a complete list of qPCR markers see (Figure 1B and
Supplemental Table 2). Initial visualization of the full dataset by unsupervised hierarchical
clustering reveals that our FACS sorting strategy, and qPCR marker panel, isolates statistically
separable populations that capture a range of transcriptional phenotypes between the fibroblast
and pluripotent states (Figure 1C). We then performed a series of statistical analyses to: 1)
describe probable trajectories followed by OSKM-infected cells; 2) measure the progress of
cellular transcriptional profiles toward a pluripotent transcriptional phenotype; and 3) determine
the order of gene activation during the reprogramming process.
2.2.2

Mapping the Trajectory of OSKM-Infected Cells Throughout
Reprogramming

As a first step in visualizing our single cell transcription dataset, we used principal components
analysis (PCA) to assess the complexity and major sources of variation in gene expression between all
cells collected in our study. This analysis reveals that the first two PCA dimensions account for 33.1% of
the observed variation, where PC1 primarily represents a cell’s distance from hESC, and PC2 primarily
captures distance from fibroblasts (Figure 2A). In addition, these two axes appear to represent distinct
trajectories followed by cells transduced with OSKM The first is a roughly linear productive trajectory
between the fibroblast and hESC groups (R2=0.60, Figure 2B) and the second is an orthogonal trajectory
leading away from fibroblast but not towards a pluripotent phenotype (herein referred to as the alternate
trajectory, or ALT). Because the productive and alternate trajectory are well correlated with the PC1 and
PC2 dimensions respectively (Figure 2C) and capture much of the variation in our dataset, we developed
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a metric to analyze our data in a 2-dimensional Euclidean space that maps each cell’s distance (relative
similarity) to the centroids of both the Fibroblast and hESC groups. In addition, we construct a Euclidean
diagonal between Fibroblast and hESC which we term the “reprogramming progression axis”. This axis
serves as a useful measurement of a given cell’s progression towards pluripotency and is a metric used in
all subsequent analysis presented here.
It is important to note that our analysis constructs likely reprogramming trajectories by sampling
partially reprogrammed cells. This approach is common among many efforts to sample dynamic
processes and is particularly ubiquitous in attempts to dissect the reprogramming process9,49,74. We apply
the standard parsimonious assumption that the shortest path defined by these samples represents the most
likely trajectory of the process. One caveat of this approach is that we cannot exclude the possibility that
progression within the observed state-space is non-linear, and may be complex and/or cyclical. These
possibilities will need to be ruled out with longitudinal live cell studies beyond the scope of this work.
Another important consequence is that while cells clearly take time to traverse the trajectory, we do not
expect progress along a trajectory to have a linear relationship with time. However, progress may be
loosely thought of as a surrogate for time but should not be strictly interpreted as such.
Interestingly, when mapping the FACS-sorted phenotypes onto our Euclidean similarity graph
we noticed that, while SSEA4 and TRA-1-60 appear in the expected order (SSEA4+ before TRA-1-60+),
the SSEA4+ and SSEA4+/TRA-1-60+ populations exhibit considerable transcriptional heterogeneity
(Figure 2D). SSEA4 positive cells are found in both the productive and alternative trajectories suggesting
that, while SSEA4 may be a reliable marker of exit from the fibroblast state, it does not necessarily
indicate that cells have moved toward a pluripotent transcriptional phenotype. Even more pronounced is
the diversity of TRA-1-60 positive cells. The transcriptional phenotype of these cells extends from a
nearly fibroblast-like profile, to a nearly ESC-like profile. The extremely high degree of transcriptional
heterogeneity we observe, even within well-defined and widely utilized FACS profiles, underscores the
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utility of single cell analysis to dissect fine differences in gene expression between partially
reprogrammed cells.
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With the phenotypic diversity of commonly utilized cell surface markers in mind, we utilized a
Self-Organizing Map (SOM) to identify separable groups along the two previously described
reprogramming trajectories in both PCA and Euclidean space (Figure 2E and F, respectively). Four of
these groups (Fib, Early, Late and Pluri) lie along the productive trajectory from Fibroblast to ESC and
the fifth encompasses cells in the alternate trajectory. It is important to note that while these groups can be
statistically distinguished from one another, we do not believe these represent discrete stages in the
reprogramming process. Further inspection reveals that progression along the productive trajectory is
characterized by the consolidation of chromatin modifier expression, an increased probability of
pluripotency gene expression, a progressive decrease in the expression of fibroblast markers and transient
expression or repression of predicted intermediate markers 9,11. Among the earliest distinctions between
the productive and alternate trajectories (Early vs Alt) is the induction of chromatin-modifying enzyme
expression. While many of these genes are expressed at low levels in fibroblasts, they are coordinately
up-regulated in the “Early” group, and become expressed at uniformly high levels in all cells progressing
towards pluripotency. In contrast, cells in the alternate trajectory down-regulate or eliminate expression of
these genes (Fig. 2G). In addition, “Alt” cells fail to upregulate the expression of early pluripotency genes
(Figure 2H) and are found at all of the time points examined, suggesting that these cells are unlikely to be
on a trajectory that ultimately leads to pluripotency. Because “Alt” cells appear to be following an
orthogonal trajectory that may lead to fates unrelated to ESC (such as transformation or apoptosis 4,133)
they were excluded from further analysis of the productive reprogramming trajectory.
Taken together these data indicate that OSKM infected cells exit the fibroblast state along two
distinct trajectories, and that the upregulation of chromatin modifiers marks a key early step towards
successful reprogramming. The rapid upregulation of chromatin modification genes is consistent with the
need for extensive chromatin remodeling prior to establishment of the endogenous pluripotent GRN
5,18,72

.
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2.2.3

Mapping Coarse Changes in Gene Expression along the Productive
Trajectory

In order to provide a rough benchmark for other literature examining transcriptional
changes in ensemble samples of partially reprogramed cells, we identified quantitative
expression differences between SOM groups along the productive trajectory (Figure 3). It is clear
from this data that specific changes in gene expression occur along different portions of the
trajectory, which suggests an underlying order to the gradual acquisition of pluripotency gene
expression during the reprogramming process. However, closer analysis reveals that there does
not appear to be tight covariance between genes activated along the progression toward
pluripotency. Representative bubble plots illustrating transcript presence and absence (Figure 3
and Supplemental Figure 2) show that genes being activated during reprogramming exhibit a
period of heterogeneity in transcript detection prior to being detected in all cells approaching
pluripotency. Quantitative analysis of gene expression levels also supports this finding (Figure 3,
Supplemental Figure 3). These plots depict gene expression levels on the y-axis, overlain with a
distribution graph showing the range of expression values within the population. A unimodal
distribution indicates uniform expression around a mean within the population, whereas a
bimodal distribution demonstrates a transcriptionally heterogeneous population (e.g. high/low)
for the gene in question. Nearly all the genes in our study exhibit this bimodal behavior at some
point along the reprogramming trajectory, before achieving a unimodal distribution as they
approach the fully reprogrammed state, however the point of bimodality varies in a gene-specific
manner. These findings demonstrate that the activation or inactivation of gene expression during
reprogramming proceeds through a probabilistic intermediate step, resulting in transcriptionally
heterogeneous cell populations, and that the timing of this transition occurs with gene specific
dynamics.
24
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In order to scan for potential differences in reprogramming gene expression dynamics
between species (mouse and human) we processed our data so that it would be roughly
comparable to that generated by Polo et al 8. As in the present study, Polo and coworkers used
FACS to isolate and measure the transcriptional profiles of a large number of partially
reprogrammed mouse fibroblasts and clustered genes based on their expression dynamics. We
compared these clusters to the dynamics of the human orthologs 122,130 represented in our dataset
(Supplemental Figure 4). While high-resolution comparison was not possible with the publically
available mouse data, most genes shared between datasets appear to exhibit similar dynamics in
the stochastic phase. That is, early mouse genes change expression early in the human trajectory,
while late genes change later in the trajectory. However, despite the coarse limits of resolution in
this comparison, several genes, including NANOG, LIN28A, POU5F1 and STAT3, appear to
change at different stages of the reprogramming process in these two species. These disparities,
while requiring more direct comparison and detailed confirmation, are consistent with distinct
differences between regulation of the pluripotent state in mouse and human cells as well as
probable differences in the starting chromatin state of loci in mouse and human fibroblasts.
2.2.4

Reprogramming is a Loosely Ordered Probabilistic Process
Effectively Modeled by Gaussian Distributions

Our observation that distinct transcriptional differences exist between PC-SOM clusters
indicates that gene expression changes during the stochastic phase of reprogramming appears to
occur in an ordered fashion. However, the coarse grained nature of this differential analysis
between statistically identifiable, but not necessarily biologically relevant groups, provides little
insight to the exact nature of the order of gene expression dynamics during the stochastic phase.
In particular, we wanted to address two specific questions: 1) Is the acquisition of pluripotency
gene expression random and gradual, with all genes approaching a pluripotent profile at a
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uniform rate over the course of the process?; and 2) Is there sub-structure within the patterns of
gene activation that would suggest the activation of modules within the pluripotency GRN? We
addressed these questions by differentiating between null and alternative hypotheses (in the form
of distribution models) predicting gene expression frequencies along the reprogramming
trajectory from MRC-5 to H9-ESC and comparing these to what we observe in our experiments.
In order to formally address the first question we modeled random gradual change in
gene expression by assigning each fibroblast and pluripotency marker a uniform rate
(probability) of change along the trajectory from MRC-5 to H9-ESC that would result in
predicted gene expression frequencies that match the observed frequencies at the start (MRC-5)
and end (H9-ESC) of the process 8. In contrast, our alternative hypothesis was that genes change
expression at specific stages of the process; in other words, gene expression during the stochastic
phase is ordered. This alternative scenario was modeled by fitting Gaussian probability
distributions to each gene such that the probability distribution was centered at the point of
greatest change in gene expression frequency along the reprogramming trajectory. In order to
model the behavior of transient genes, and to help calibrate differences between goodness of fit
between models, we also built more complex models with two probability distributions, which
allowed us to model genes that change expression at two points in the process. Changes in gene
expression frequency predicted by our null model are linear, while the alternative model with
one probability distribution predicts sigmoidal changes and the two distribution model allows for
more complex dynamics of change in gene expression frequency, such as transient activation or
inactivation. The goodness of fit of each model to our observed data was then measured for each
gene in both PCA and Euclidean space using an F-test statistic. Because goodness of fit typically
scales with the number of parameters in a model, the Gaussian models were penalized for added
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parameters using a corrected Akaike Information Criterion (AIC, see Materials and Methods).
The results of these tests can be found in (Figure 4A-D and Supplemental Table 3).
As demonstrated in Figure 4B, the vast majority of genes reject the null hypothesis (Fstatistic > F-Critical) in favor of a Gaussian model. Note that many genes that reject the null
hypothesis do so very strongly, while the few genes that better fit linear dynamics do so only
marginally (Figure 4C). In addition, most genes that do not reject the uniform model exhibit little
or no change over the course of reprogramming or have noisy expression profiles. Both of these
observations suggest that most gene expression changes occurring during the stochastic phase are
not simply gradual acquisition of an ESC-like expression frequency, rather they turn on and off
at specific points in the process.
To further assess the confidence with which random change (uniform probability
distribution) in gene expression during the stochastic phase can be rejected by our models
(Gaussian probability distribution) is to compare the explanatory power of each model, as
adjusted for the additional parameters required in each more progressively complex scenario.
Figure 4D shows that while one normal distribution significantly improves AIC (lower is better),
two normal (or even three normal - data not shown) do not add much explanatory power. One
exception is for genes that exhibit transient expression changes, the fits for which are shown in
Supplemental Figure 5. For this reason, we suggest that gene expression dynamics during the
stochastic phase are best described as events occurring at specific points in the process, where
most gene’s expression dynamics are well described by a single normal probability distribution
centered at the point of maximal rate of change. Genes that change at very specific points in the
process have very tight probability distributions, while genes with less precise dynamics display
broader probability distributions (approaching the uniform distribution of our null model).
28
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In order to compare dynamics between genes, we modeled each gene in our study using
single Gaussian probability distributions as described above. All model fits are illustrated in the
Supplemental Figure 6. One example fit is illustrated for CDH1 in Figure 5A. In this figure the
black dots represent measured expression frequencies of CDH1 in sliding windows along the
inferred reprograming trajectory. The red curve shows gene expression dynamics modeled as a
Gaussian probability distribution fit to the experimental data and the blue line illustrates
expression frequencies predicted by that probability curve.
When the dynamics of several genes are compared in one graph (Figure 5B-E) it is
readily apparent that: 1) genes are activated or inactivated at different points during the
reprogramming process; 2) genes have specific stringencies in their activation dynamics (some
genes change at fairly specific stages, while others change over almost the entire course of the
process); and 3) there is considerable overlap in the expression probabilities of individual genes.
Most genes are activated or repressed with diffuse dynamics, while several (NANOG, CDH1,
ZFP42, ZIC3 and OTX2) change at more specific stages of the reprogramming process. The
diffuse dynamics and broad windows of activation observed for most pluripotency markers is
consistent with the longitudinal observation that the expression of the surface antigens SSEA4
and TRA-1-60 in iPSC colonies are not strongly predictive of successful reprogramming events
49,51

. Taken together, this data strongly supports the hypothesis that rather than being a strictly

ordered or strictly random process, the stochastic phase of reprogramming is an ordered
probabilistic process. Seen in this light, prior ordered and random models can be coherently
united

56,124,134

.
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2.2.5

Changes in Pluripotency Gene Expression During the Stochastic
Phase Do Not Show Hallmarks of Activation of the Pluripotency Gene
Regulatory Network

Having observed ordered dynamics in the stochastic phase, we sought to determine if
there was any indication that this order might arise from the partial activation of the endogenous
pluripotency GRN. Current models suggest that partially reprogrammed cells enter a late, rapid
deterministic phase that is controlled by activation of the endogenous pluripotency GRN and
may be marked (in mouse cells) by the activation of the endogenous Sox2 locus56,135.
Alternatively, order could emerge gradually or piecemeal during the stochastic phase. A
hallmark of concerted gene regulation as exerted by a GRN, is strong correlation (or anticorrelation) between gene expression patterns 8,110,124. Our model provides a powerful way to
detect correlated gene expression that lies above the background correlations inherent during
reprogramming (i.e. pluripotency markers all become expressed in fully reprogrammed cells). In
this case, our null hypothesis is that during the stochastic phase there is no dependency between
genes and that all correlation between gene expression in individual cells results simply from the
increase in frequency of pluripotency markers as cells approach an ESC-like transcriptional
profile. Our alternative hypothesis is that some pluripotency genes may be co-regulated (or
cross-regulate) during the stochastic phase and would thus display higher than background levels
of co-expression (as measured by correlation). To test these hypotheses we used the probability
profiles of each gene to generate a simulated data set in which gene expression is determined
only by the probability profile of each gene, with no dependencies between genes. The resulting
dataset accurately recapitulates the individual dynamics of each gene in our dataset, and provides
pairwise correlation values that are solely dependent upon the convergence of all pluripotency
markers on uniform expression in ESC. We then compared pairwise correlations between genes
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in this background data set with the real correlations observed in our single-cell transcript data
(Figure 6).
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Interestingly, the only correlations we find rise above background expectations occur
between a set of chromatin regulators that distinguish between entry into the productive
trajectory and entry into the alternative trajectory (Figure 6). This coordinated activity is likely
the result of activation of the c-MYC GRN, which is known to be activated upon OSKM
induction, and is largely limited to genes with a permissive chromatin state in fibroblasts as is the
case for many chromatin modifier genes 136,135 (Figure 6, inset). In contrast, none of the
correlations between members of the pluripotency GRN rise above background expectations,
despite their overall increase in expression frequency as cells approach an ESC-like expression
profile. We therefore accept the null hypothesis: that despite the ordered activation of genes in
the pluripotency GRN during the reprogramming process, there is no evidence for gradual or
modular activation of the pluripotency GRN during the stochastic phase of reprogramming. An
important corollary that follows from this result is that the dynamics of gene activation during
the stochastic phase appear to depend only upon the local properties of each gene, rather than the
sequential activation of precursors in the GRN. Of course, the numbers of genes we analyze in
our study somewhat limits the power of this analysis, and a more comprehensive single-cell
study measuring many more genes might uncover obligate relationships between genes that are
not apparent in our core pluripotency GRN gene set.
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2.3 Discussion
In this study we present a rigorous single cell analysis of reprogramming in human cells and
show that the stochastic phase of reprogramming of human fibroblasts by OSKM is an ordered
probabilistic process which can be simply modeled using independent Gaussian distributions. An
advantage of our approach lies in the fact that it makes no a priori assumptions about the
progression of cells toward pluripotency, based on time or surface marker expression, both of
which are poor indicators of reprogramming progress. In addition, the simplicity of our model
and its exceptional fit to our observed expression dynamics provide a tractable framework for
further dissecting the rate-limiting aspects of reprogramming. The results of this work also unify
existing ordered and random models of the stochastic phase of reprogramming 11,49,52,55,110,123 and
are consistent with observations from both population level and single cell studies of gene
expression changes during reprogramming 9,49,56. The ordered nature of the stochastic phase is
readily apparent in the distinct, gene-specific expression dynamics we observe during
reprogramming, while the probabilistic nature of the process is evident in broad gene-specific
expression dynamics over large portions of the reprogramming trajectory (Figure 5 and Figure
7), and the apparently independent control of gene expression dynamics during the stochastic
phase (Figure 6). These findings are consistent with a recent study by Tanabe et al. 57 that
suggests the TRA-1-60+ phenotype is unstable and transcriptionally heterogeneous and that
stabilization of the TRA-1-60+ population is a critical rate limiting step in reprogramming. Note
we suggest retaining the term “stochastic” for this phase of the reprogramming process, in that
stochastic can be used to describe ordered probabilistic events, and does not necessarily imply
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complete randomness. The use of the term stochastic is especially appropriate given the
independence of activation dynamics of key genes in the core pluripotency GRN.
One consequence of the independent activation of genes during reprogramming is that an
extremely wide variety of cell states are present during the reprogramming process, which gives
the overt appearance of disorder. Thus, while any given partially reprogrammed cell’s gene
expression pattern may appear to be random, the probabilities of expression of individual genes
are clearly biased towards specific points along the reprogramming trajectory. One implication
of these findings is that any single marker is unlikely to be effective at determining the extent to
which a given cell has been reprogrammed 49,137.
We note that variations in the cell cycle could contribute to the transcriptional
heterogeneity of a subset of genes in our dataset. However recent studies in hESC have shown
that the transcription of genes associated with pluripotency does not fluctuate during the cell
cycle 138, suggesting that cell cycle status is unlikely to have a major impact on our analysis of
the activation of the pluripotency GRN. In addition, the persistence of cyclin transcripts
throughout the cell cycle and their considerable post-transcriptional regulation in ESC’s 139,
precludes strong inference of cell cycle status from transcriptional measurement of a single cellcycle regulator.
Another possible source of transcriptional heterogeneity between partially reprogrammed
cells in our cultures could be the delivery of O, S, K, and M on individual vectors (as is standard
in widely utilized human reprogramming protocols). However the broad agreement of expression
dynamics over the course of reprogramming between our results using individual viral delivery,
and those reported by Polo et al using an inducible, polycistronic construct in a clonal cell line,
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suggests that viral heterogeneity does not fundamentally affect the order of gene expression
dynamics, or the shape of the trajectory of cells undergoing the reprogramming process.
Furthermore, the initial description of the highly heterogeneous nature of the stochastic phase by
Buganim et al was also derived from data using clonal cells expressing OSKM from an inducible
polycistronic OSKM construct. Thus, the stochastic nature of this phase does not appear to be a
direct consequence of OSKM heterogeneity. However, these results do not rule out the
possibility that each of the OSKM factors have distinct roles in various stages of the
reprogramming process, nor that heterogeneity in OSKM content will be observed across the
partially reprogrammed population of cells. Indeed, understanding the role of each factor in the
reprogramming process and the critical window for the action of each represents an important
goal of future work.
A likely explanation for the apparent lack of deterministic behavior during the stochastic
phase may be the existence of as yet unidentified, gene-specific factors that restrict the rate of
transcription activation by OSKM. One compelling candidate for these factors is the local
chromatin architecture of the pluripotency genes in the starting somatic cell type. Indeed,
epigenetic remodeling was implicated as a major rate limiting step in even the earliest days of
somatic cell reprogramming using nuclear transfer 21,125 and is almost certainly one of the most
important probabilistic events limiting the rate and efficiency of reprogramming. Many reports
have experimentally validated this hypothesis by demonstrating that global chromatin
reorganization is critical for successful reprogramming 5,50,66,69. Because many of the required
changes in chromatin state appear to occur in a slow and probabilistic fashion 43,140,141 it is likely
that these changes limit the rate at which exogenous OSKM can activate the endogenous

39

pluripotency GRN thus limiting the efficiency and speed of reprogramming and endowing the
majority of the process with stochastic dynamics.
Our finding, that enhanced expression of chromatin modifiers is a hallmark of entry into
productive reprogramming complements several studies demonstrating that successful
reprogramming requires the gradual erosion of epigenetic barriers to activation of the
pluripotency GRN by OSKM 4,5,65,67,69. This event is likely governed by the activity of c-MYC,
which together with KLF4, acts early in reprogramming to activate loci with permissive
chromatin states, including many chromatin modifier loci in fibroblasts 66,67. In addition, many
treatments known to enable chromatin remodeling have been shown to enhance the rate and/or
efficiency of the reprogramming process 61,65,142,143, while, conversely, knocking down factors
required for such epigenetic changes can inhibit or prevent successful reprogramming
61,65,111,142,144,145

. However, with the exception of some very early events 66,67 the order and

precise identity of chromatin modifications required for successful reprogramming is not yet well
known. By precisely describing and modeling gene expression dynamics during the stochastic
phase the present study provides a quantitative framework for dissecting these key rate limiting
steps and will enable the mechanistic dissection of interventions known to accelerate or enhance
the efficiency of the reprogramming process.

Chapter 3

Comparison of Monocistronic and Polycistronic Reprogramming
Methods in Two Cell Types

3.1 Introduction
Reprogramming terminally differentiated cells to a pluripotent state by exogenous expression of
the Yamanaka factors OCT4, SOX2, KLF4 and c-MYC (OSKM) has the potential to revolutionize many
aspects of modern medicine. However, despite years of research this process remains highly inefficient
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and produces considerable cellular heterogeneity, problems that must be overcome before this technique
can be used clinically. In the years following the first reports of OSKM-mediated reprogramming,
several methods have been developed to reprogram cells to pluripotency in an effort to increase the
efficiency and quality of iPSC generation. This includes using different methods of delivering the OSKM
factors, including retroviral, lentiviral and episomal vectors, mRNA/miRNA transfection, as well as the
use of additional factors such as NANOG, LIN28, SALL4 and others 6,31,38,77,146. While many of these
approaches have increased the efficiency and/or rate of reprogramming, at present it is unclear how these
results manifest at the molecular level and such knowledge could provide insight into common
mechanisms necessary to acquire pluripotency.
Many efforts to illuminate the molecular underpinnings of reprogramming have been complicated
by the inefficiency and temporal asynchrony of the process. Only 0.01-1% of cells reaches the
pluripotent state and do so at different rates over the course of a 3-4 week period. As a result, the majority
of studies conducted to date that rely on bulk measurement of heterogeneous populations of cells are
inherently biased towards analyzing unsuccessful reprogramming events. Thus, measurement of
transcriptional or other events leading to pluripotency may be obscured. To overcome this limitation of
bulk analysis our group and others have used single cell analysis and mathematical modeling to
deconstruct the transcriptional and protein-level changes occurring in cells undergoing reprogramming
10,56,58,147

. By profiling individual cells en route to pluripotency we are better able to assess how the

pluripotency gene regulatory network (GRN) becomes activated in response to the OSKM factors.
Specifically, whether this activation happens as a series of concerted deterministic events, or occurs
gradually over the length of the process. Equally important is the ability to measure what appear to be
unsuccessful reprogramming events leading to trajectories other than pluripotency. Identification of
common features in divergent cells can reveal events preventing cells from becoming iPSCs.
This previous work proposed a model where acquisition of pluripotency is primarily limited by an
early probabilistic or stochastic phase. During this phase, genes associated with pluripotency activate
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independently , lacking coordinated expression characteristic of a stable, pluripotent state 11,55,56,134. This
period can persist for a variable length of time, after which cells that have made the requisite epigenetic
and transcriptional changes, activate the pluripotency gene regulatory network (GRN) and are stabilized
in the iPSC state 56,91,148. The stabilization of this network requires precisely controlled levels of OSKM
expression67,101. Premature inactivation of exogenous OSKM fails to generate iPSCs52,104 and conversely,
failure to inactivate the OSKM cassette forces cells to an alternate ESC-like state, distinct from iPSC149.
Given the relationship between factor stoichiometry and efficiency, it is important to assess how
variations in reprogramming method impact the acquisition of pluripotency.
Comparison of monocistronic and polycistronic viral delivery of the 4 factors is of particular
interest, as this remains the most widely utilized reprogramming strategy in the human system2,150.
Monocistronic delivery allows flexibility in the stoichiometry of factor delivery due to random integration
of the individual constructs, however many cells receive combinations of factors that are suboptimal for
reprogramming, or may cause cells to take a different trajectory to the pluripotent state101,151. In contrast,
polycistronic delivery fixes the ratio of factor delivery at 1:1:1:1, a ratio that may not be optimal for
successful reprogramming, but guarantees that all transfected cells will carry a full complement of the
reprogramming factors. In separate studies it has been demonstrated that mono and polycistronic systems
reprogram cells at different efficiencies in mouse, 0.01% and 0.5%, respectively, and human 0.2% and
1.5%,respectively 2,28,32,33,145, however no direct comparison of these methods exists currently.
Furthermore, species-specific differences in the molecular events leading to pluripotency exist between
mouse and human152, further complicating the comparison of these two techniques and underscoring the
importance of studying reprogramming in human cells for clinical purposes.
The majority of studies to date have focused on reprogramming fibroblasts due to their simplicity
of isolation, however dozens of other cell types have been successfully reprogrammed. The starting cell
type has been demonstrated to have a significant effect on both the efficiency of the process, as well as
the differentiation capacity of the resulting iPSCs. There is evidence to suggest that these effects are due
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to unique epigenetic landscapes in different cell types which can affect the accessibility of pluripotency
loci and consequently their ability to be activated by reprogramming factors5,50,69,153. This same epigenetic
landscape also results in a ‘memory’ of the cell’s starting identity, making differentiation back to the cell
type of origin more efficient than generation of more therapeutically relevant alternatives118,154,155. Thus,
the starting cell type can have a dramatic influence on the outcome of the reprogramming process but
again, no analysis of whether this affects the acquisition of pluripotency has been performed.
In this study, we apply single cell transcript analysis to compare the transcriptional dynamics
underlying the acquisition of pluripotency in monocistronic and polycistronic OSKM systems. These two
delivery methods were tested in both MRC-5 and BJ fibroblasts. We demonstrate that polycistronic viral
delivery produces significantly higher reprogramming efficiencies compared with monocistronic delivery
and that this effect is due in part to premature inactivation of the individual O, S, K or M vectors in the
monocistronic method. In addition, we show that the activation of key pluripotency loci such as NANOG,
OCT4, LIN28 and DNMT3B occurs earlier in the polycistronic condition and that these cells progress
more uniformly towards pluripotency. Finally, we compare polycistronic reprogramming between MRC-5
and BJ fibroblast cells and reveal that while the order of gene activation is similar between cell types,
MRC-5 and BJ cells take divergent paths upon factor induction, followed by convergence later in the
reprogramming process.

3.2 Results
3.2.1

Monocistronic and Polycistronic Reprogramming Efficiency

As an initial assessment of reprogramming efficiency between the monocistronic (Mono) and
polycistronic (Poly) reprogramming methods, we analyzed the percent of SSEA4 single-positive (S+T-)
and SSEA4/TRA-1-60 double-positive (S+T+) cells by FACS, markers associated with early and late
reprogramming respectively49,51,137. We observe a significant enrichment of S+T- cells in the Poly,
compared with the Mono condition which increased from a 2-fold difference at D4, to >8-fold at D14.
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This trend is apparent for TRA-1-60+ cells as well, where Poly exhibits ~15-fold increase at both time
points analyzed (Figure 8C). To determine whether the difference in SSEA4 and TRA-1-60 expression
between conditions correlated with reprogramming efficiency, we stained and counted AP+ colonies at
D21 and D28. Poly cells have 10-fold more AP+ colonies than Mono cells at D21, and this increase is
even more pronounced at D28, the point at which colonies are typically picked to establish iPSCs (Figure
8D). This corresponds to an efficiency of ~5% and 0.5% for Poly and Mono, respectively. This is
consistent with previous reports showing a 10-fold increase in reprogramming efficiency between the two
conditions, albeit in separate studies2,146,150. In our experience, Mono colonies tend to be broad and cover
more area than Poly colonies which are small and punctate. Example colonies are shown in Figure 1B. To
ensure this difference in morphology did not skew our colony counting results we also measured the total
area of the plate covered by AP+ cells. We still observe significantly higher AP-positivity in Poly
compared with Mono (Figure 8E). These findings also hold true in BJ fibroblasts reprogrammed with
Mono and Poly as shown in Supplemental Figure 7.

3.2.2

Experimental Design

In order to measure transcripts in individual cells at various points in the reprogramming process,
we infected MRC-5 fibroblasts with a polycistronic construct containing all four Yamanaka factors
(Poly). We then isolated cells by FACS at D4, D7, D11, D14 and D21 using the surface markers SSEA4
and TRA-1-60 to enrich for early (SSEA4+/TRA-1-60-) and late (SSEA4+/TRA-1-60+) reprogramming
events, respectively (Figure 8A). These cells were sorted into 96-well PCR plates and processed through
our single cell pipeline and qPCR was performed on the Fluidigm Biomark against a panel of 96 markers
(Supplemental Table 4). In addition to profiling 80 reprogramming cells, we also profiled 16 MRC-5
fibroblasts and 32 H9 and H1 hESCs to represent the beginning and end points of the process,
respectively (Supplemental Table 5). The Poly dataset was trimmed for comparison with our previously
published MRC-5 Mono data which contains cells sampled at days 4, 7 and 14, measured for the
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expression of 48 genes, all of which are present in the larger 96 gene panel analyzed in the Poly
experiment149.
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3.2.3

Progression of Individual Cells in Mono and Polycistronic
Reprogramming

To visualize the progression of cells from the fibroblast to the pluripotent state, we used our
previously described method of plotting cells based on their relative distance from both the fibroblast and
hESC populations149 (Figure 9A), overlaid with the surface markers used to isolate the cells. This method
is agnostic to the time point of collection since progression through the reprogramming process is
asynchronous and poorly correlated with time58. Using this approach, we observe a striking increase in
progress of S+T- cells in the Poly condition, with some cells overlapping the hESC population, whereas
S+T- Mono cells are only present in the first half of the reprogramming trajectory. We also notice that
S+T+ Poly cells are very tightly clustered around the hESC population while S+T+ Mono cells span a
large portion of the reprogramming trajectory. The increased progression in the Poly condition is
accompanied by greater reprogramming synchrony compared with Mono, as revealed by the tighter
distribution of cells along the reprogramming trajectory, maintained over time (Figure 9B). The
distribution of S+T- Mono cells across the reprogramming trajectory broadens between D4 and D14,
suggesting that either some cells are initiating reprogramming at the later time point, or that not all cells
expressing SSEA4 are progressing through the process at the same rate, commonly referred to as variable
latency. This is in contrast to Poly cells, which all progress towards an ESC-like transcriptional profile by
D14.
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3.2.4

Generating a Logistic Regression Model

It has been proposed that the period of variable latency results from the stochastic and
uncoordinated activation of pluripotency loci required to drive cells towards the pluripotent state. Because
cells reprogrammed by the polycistronic method progress more uniformly towards the ESC state than
monocistronic reprogramming cells, we asked whether the activation of pluripotency loci, or inactivation
of fibroblast-associated loci, was more tightly coordinated in Poly cells. To this end, we improved upon
our published method 149(Methods) to model the expression changes of genes along the reprogramming
trajectory from fibroblast to hESC. Our new method gains higher accuracy while reducing the number of
parameters to minimize bias compared with our previous model. We define the reprogramming trajectory
by projecting cells into a 2-dimensional PCA space and fitting a polynomial curve through the dataset.
We then find the shortest distance from each point to the curve and assign a value for that cell along the
trajectory. These values are scaled between 0 and 1, representing the beginning and end of the process,
respectively. For each gene in our dataset, we reduce the data to presence/absence calls and fit a logistic
regression to the data, representing a continuous measure of the probability of detecting a given gene over
the course of reprogramming. In addition, we gain information about when a gene is activated in the
majority of samples and how rapidly that change occurs based on the point of greatest change in
probability and the steepness of the curve. An example fit curve is shown in Figure 10A with dashed lines
representing bootstrapped confidence intervals around the fit curve. Model fits for all genes can be found
in Supplemental Figure 8. The expectation of this model is that conditions where gene expression changes
rapidly correspond to a reprogramming process with fewer barriers to the transcriptional
activation/inactivation events necessary to reach pluripotency and more closely resembles a deterministic
rather than probabilistic process.

3.2.5

Assessment of Two Reprogramming Methods Using a Logistic
Regression Model

To compare the model fits between conditions we separated activating and inactivating genes and
plotted the point of greatest slope and the bootstrapped confidence intervals in Figure 10B. We notice
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significantly earlier points of activation in Poly compared with Mono reprogramming (Figure 10C and E)
for a subset of genes in our panel. This includes several key pluripotency loci such as POU5F1, NANOG
and DNMT3B and may in part explain the improvement in reprogramming efficiency. Interestingly,
despite earlier changes in gene expression in Poly cells, the order in which these genes are
activated/inactivated is strongly correlated between the two conditions (Spearman’s r = 0.75). This is
further supported by the high correlation of gene loadings from independent PC analysis of Mono and
Poly cells in the PC1 dimension (Figure 10D). The loadings provide a measure of when and how strongly
each gene contributes to progression through the process and therefore, strong correlation in the loading
scores indicates a common path to pluripotency for Mono and Poly reprogramming. It is important to note
that while the two methods as a whole follow a similar path to the pluripotent state, the activation of a
given gene remains a probabilistic event under our model. Thus, the order in which an individual cell
activates/inactivates these loci is not fixed (ie is not deterministic). Consistent with this notion, we do not
see a narrowing of the activation window as there is no significant difference in the slope of the activation
curves between conditions (Figure 10F), nor do we observe increased correlation between genes in the
Poly condition (Figure 11A-C). Taken together, these results suggest that while some pluripotency genes
are activated earlier in the process in Poly reprogramming, coordinated GRN activity or deterministic
behavior is not observed.
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3.2.6

Heterogeneous Expression of Exogenous OSKM Factors

Given that gene activation/inactivation is only slightly enhanced in polycistronic reprogramming
and that the overall dynamics of the process appear similar between conditions, we looked for other
factors contributing the poor efficiency of Mono reprogramming in both MRC-5 (Figure 12) and BJ
(Supplemental Figure 9) fibroblasts. We hypothesized that OSKM heterogeneity could contribute to the
low efficiency of Mono reprogramming since the factors are delivered on separate viral particles. To this
end, we included SYBR primers targeting synthetic 3’-UTR regions present in the individual OSKM
constructs (Supplemental Table 6) allowing us to measure the expression of the transgenes in all single
cells collected for this experiment in addition to the 48-gene panel analyzed above. Looking at all four
factors collectively it is apparent that a vast minority of cells express all four exogenous factors, with
most cells expressing only one or two of the transgenes, including cells close to the hESC state (Fig 12A).
Interestingly, cells that express the full complement of reprogramming factors are clustered early in the
reprogramming trajectory, with no 4-factor containing cells progressed beyond the 50% mark. In contrast,
most cells late in the trajectory express only one or two factors, typically either OCT4, MYC or both (Fig
12B). As expected, nearly all cells progressing along a previously described alternate trajectory away for
both fibroblast and hESC lack expression of all reprogramming factors except MYC, illustrating the
requirement of OSK expression for productive reprogramming.

3.2.7

Expression Patterns of Endogenous and Exogenous OSKM in
Monocistronic Reprogramming

The considerable heterogeneity of transgene expression in Mono reprogramming cells led us to
compare the expression of the endogenous (ENDO) and exogenous (EXO) copies of the OSKM factors to
see if cells lacking transgene expression exhibited activation of the endogenous copy (Fig 12B). Nearly
all Mono cells express exogenous MYC, while only three cells express the endogenous form. This can
likely be attributed to the profound proliferative effects of high levels of MYC expression4,66,136,135, which
results in expansion of this population and increases the likelihood they are sampled in our experiment. In
contrast, EXO-KLF4 is detected in very few cells, however the endogenous form is present in the
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majority of samples. This is consistent with the role of KLF4 in promoting MET, an essential step in
reprogramming that occurs late in the process74,156,157. Also, in agreement with previous reports that
OCT4-high SOX2-low is an optimal factor stoichiometry for reprogramming58,101, we notice the
expression of exogenous OCT4 and SOX2 exhibit opposite patterns, with EXO-SOX2 expressing cells
confined to the first half of the reprogramming trajectory while EXO-OCT4 cells persist until the later
stages of reprogramming (Fig 12B). In addition, many late-reprogramming cells expressed both the
ENDO and EXO forms of OCT4 further supporting this notion. Surprisingly, ~50% of late
reprogramming cells fail to express either ENDO or EXO-SOX2. In mouse, SOX2 is required for entry
into the deterministic phase and stabilization of the pluripotent state. The absence of SOX2 in some of our
late reprogramming cells begs the question of whether or not these cells will successfully reprogram. In
addition, it is unclear whether these cells were capable of progressing to the late stages of reprogramming
in the absence of SOX2 expression, or if the SOX2 virus was prematurely inactivated prior to completing
the process.
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3.2.8

Transcriptional Analysis of Low-GFP Reprogramming Cells

To address this question we took advantage of the fact that our monocistronic OSKM vectors coexpress GFP along with each reprogramming factor, allowing selection of cells with low viral content as
indicated by low-GFP expression. These cells were sorted by FACS and we assessed their transcriptional
profile using our 48-gene panel. When added to our reprogramming trajectory (Fig 12C), these cells look
nearly identical to fibroblasts and both S+T- and S+T+ Low-GFP cells exhibit impaired progression
compared with their High-GFP counterparts (Fig 12D). This would suggest these cells failed to respond
to the OSKM cocktail however, Principal Component Analysis reveals the Low-GFP cells are a distinct
population and separate from non-reprogrammed fibroblasts along the PC3 axis (Fig 12E). This
separation is due to the expression of the late reprogramming genes ZIC3 and OTX2 in these cells,
despite the failure to activate core pluripotency loci including OCT4, NANOG, SOX2 and ZFP42
(REX1) and the persistence of fibroblast gene expression (LOX and LUM) (Fig 12F). The expression of
ZIC3 and OTX2 in the Low-GFP population indicates that these cells have reached the late stages of
reprogramming, but collapsed back to a Fibroblast-like state due to premature loss of transgene
expression. Alternatively, cells may have only been infected with a subset of the reprogramming factors,
following a reprogramming trajectory not typical of cells receiving the full complement of OSKM.

3.2.9

Reprogramming Using Three-Factor Combinations OSKM

We tested this hypothesis explicitly by generating all possible 3-factor combinations (SKM,
OKM, OSM and OSK), removing each factor from the STEMCCA polycistronic vector and measuring
the reprogramming trajectory of infected cells. Attempts to reprogram cells with any of these 3-factor
combinations failed to produce any AP+ colonies and resulted in a significant reduction in SSEA4+ cells
(Supplemental Figure 10A). These cells also fail to productively reprogram, moving away from fibroblast
but not towards hESC (Fig 13A) as evidenced by minimal expression of both fibroblast and pluripotency
genes in our panel. This reduced expression is not due to lack of cell viability or the induction of
apoptosis however, indicating these cells follow a trajectory that cannot be measured using our existing
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marker set (Supplemental Figure 10B). K-means clustering of the 3-factor reprogramming conditions
along with the MRC-5 Mono dataset reveals that this trajectory is equivalent to the Alternate trajectory
we identified previously149 and suggests that Mono cells in this Alternate group are also cells that failed to
receive the full complement of OSKM (Fig 13C).
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3.2.10 Trajectory of BJ and MRC-5 Fibroblast Lines in Polycistronic
Reprogramming
Having determined that premature inactivation of the individual OSKM factors is a major
weakness of Mono reprogramming, we turned our attention to comparing the dynamics of pluripotency
gene expression between two fibroblast cell lines, BJ and MRC-5, using the polycistronic method. To this
end, we compared MRC-5 and BJ cells reprogrammed with polycistronic OSKM and analyzed the
expression of 96 genes (as described above). In our system, BJ fibroblasts exhibit ~3x greater efficiency
than MRC-5, as determined by the number of AP+ colonies at days 7, 14, and 21 (Supplemental Figure
7). Thus, we next sought to determine whether this difference in efficiency was evident in the trajectories
of each reprogramming cell type, or in the expression of individual genes. Comparing the progression of
cells over the time course of reprogramming shows little difference in the S+T- and S+T+ cells from both
cell types and, as expected, S+T+ cells progress uniformly towards pluripotency, while S+T- exhibit a
larger distribution due to variable latency(Fig 14 A-B). In addition, visualizing the trajectories in PCA
space shows that the majority of the process looks identical between cell types in the first 2 PC
dimensions, which cumulatively capture ~35% of the variance(Fig 14C). Including the PC3 dimension
(5% variance) however, reveals a slight divergence of the two trajectories early in the process, followed
by convergence near the hESC state (Fig 14D). This observation is reiterated by plotting each cell type
side-by-side in its own PC space. An initial comparison of the PCA shows both cell types exhibit a
similar distribution of reprogramming intermediates as determined by the amount of variation captured by
each PC dimension (Fig 14E). Comparison of the gene loadings between the MRC-5 and BJ PC analyses
reveals strong correlation in PC1 (Spearman r = 0.95) and PC2 (Spearman r = 0.72) dimensions, while
correlation in PC3 is weak (Spearman r = 0.59) (Fig 14F). This again suggests nearly identical gene
expression dynamics between the two cell types with subtle differences.
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3.2.11 Gene Expression Dynamics in BJ and MRC-5 during Polycistronic
Reprogramming
To determine what genes specifically contribute to the slight differences in the reprogramming
trajectories of BJ and MRC-5 fibroblasts, we utilized our model to compare the point of activation of
genes between conditions. Example fit curves for increasing and decreasing genes are shown in Fig 15A
and E, respectively. The complete set of fit curves is displayed in Supplemental Figure 11. We again use
box and whisker plots to represent the mean and bootstrapped confidence intervals of the fit curves for
both activating and inactivating genes (Fig 15B and F). A delay in the activation of several genes (Fig
15B and D, red highlight) is immediately apparent in MRC-5 cells early in the trajectory. These include
key pluripotency genes such as NANOG, POU5F1, DNMT3B and LIN28. As expected, genes late in the
trajectory exhibit nearly identical activation patterns, consistent with the observation that the trajectories
converge near the ESC state. We also observe delayed inactivation of the fibroblast marker LOX and an
inhibitor of MET, SNAI2, in MRC-5 cells (Fig 15F and H, red highlight). For both activating and
inactivating genes, we see the same degree of correlation between genes in both conditions (Fig 15C and
G), indicating the interactions between genes are consistent in BJ and MRC-5 reprogramming.
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3.3 Discussion
In this study we performed a side-by-side comparison of Polycistronic and Monocistronic
reprogramming in human fibroblast cells. Our primary finding is that reprogramming by the Polycistronic
method results in a 10-fold increase in efficiency over Monocistronic reprogramming and that this
difference is due in part to the premature inactivation of the individual OSKM factors in the
Monocistronic condition. While it has been previously documented that factor expression decreases over
the course of reprogramming52,158, this was thought to represent cells entering the pluripotent state.
Inactivation of the reprogramming factors is generally considered to be a late event in the reprogramming
process and is associated with the generation of stable iPSC lines49,97. Our study represents the first report
that premature inactivation of OSKM can occur amidst productive reprogramming and results in a
collapse of cells back to a fibroblast-like state. These cells exhibit signatures of productive
reprogramming, in particular, the expression of the late reprogramming genes ZIC3 and OTX2, however
they fail to activate the core pluripotency circuitry and continue to express markers of the fibroblast state.
We exclude the possibility that these failed reprogramming events arise from cells receiving an
incomplete complement of OSKM by demonstrating that cells lacking any one of the 4 factors fail to
reprogram. Our analysis of transgene content in productively reprogramming cells demonstrates that a
particular stoichiometry is optimal for pushing cells towards the pluripotent state. Specifically, high levels
of OCT4 and low levels of SOX2 are favored in cells that have reached an ESC-like transcriptional
profile, while KLF4 expression is consistent throughout the process, in line with previous reports58,151.
The robust detection of MYC throughout the process is expected due to the rapid expansion of MYC
expressing cells and this increase in cell cycling has been shown to greatly enhance the efficiency of
reprogramming135. Importantly, it has been previously shown that there is no selective inactivation of any
of the 4 reprogramming factors in iPSCs151 and thus, the differences we see in OSKM content reflect a
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bias for particular combinations selected for in late reprogramming events (ie. TRA-1-60+ cells) and do
not result preferential inactivation of any one factor.
By examining the trajectories followed by cells reprogrammed with either Mono or Poly viruses,
we notice that cells from the Mono condition exhibit a delay in the activation of several pluripotency loci
including POU5F1, NANOG, DNMT3B and LIN28 compared with Poly reprogramming. We also
observe a similar delay in the activation of these same loci in MRC-5 versus BJ fibroblasts. The period
preceding the activation of the core pluripotency circuitry is referred to as latency, which is thought to be
a major rate-limiting step in generating iPSCs. Our observation that latency is increased in the two
conditions with relatively lower efficiencies (Mono and MRC-5) lends support to this notion and to our
knowledge, is the first time this phenomenon has been measured between distinct conditions. It is
commonly believed that latency results from the remodeling of the epigenetic landscape to allow the
activation of pluripotency loci and it is expected that different factor stoichiometries or starting cell types
would affect the rate at which this occurs5,50,66,101,125,158. If true, this would imply BJ cells have a more
permissive chromatin state at some loci than MRC-5 fibroblasts, facilitating their activation. A rigorous
comparison of reprogramming in cell types with divergent chromatin states would directly address this
hypothesis and represents an important future direction of this work.
Despite the differences observed early in the process, cells from all conditions activate
pluripotency genes in a similar probabilistic order following the period of latency, suggesting a common
mechanism in establishing pluripotency. The convergence on a common trajectory late in the process
resembles the deterministic phase described by Buganim et al, however in our system these gene
activation events are independent and probabilistic and thus we don’t believe that our observation
represents a strictly deterministic process. It is also somewhat surprising that different reprogramming
conditions result in similar reprogramming trajectories given the variation in quality and differentiation
potential of iPSCs derived from these different methods31,159. This implies that variation in iPSC
phenotype results not from differences in how the pluripotency network is established but is likely due to
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differences not analyzed in our study. This could result from differential expression genes whose
expression alter iPSC phenotype, or could occur at the epigenetic level, as has been shown for the DioDlk3 locus in mouse101.
In contrast to the similarities between BJ and MRC-5 at the transcript level, the surface markers
SSEA4 and TRA-1-60 label slightly different populations between cell types. While the reason for this is
unclear, it illustrates the impact of cell type on selecting informative biomarkers to isolate cells from
different parts of the reprogramming process. SSEA4 and TRA-1-60 are also unique in that they are the
only markers examined in our study that exhibit a strict order of activation; SSEA4 turns on before TRA1-60 and all TRA-1-60+ cells are also SSEA4+. This is very different from the probabilistic order
observed at the transcript level for the majority of genes in our panel and it begs the question as to
whether the process is more highly ordered or deterministic at the level of protein expression. Recently
several groups have begun to explore the dynamics of the proteome during reprogramming, however this
has not yet been coupled with transcriptional analysis and all studies to date have been performed in
mouse. Indeed, this remains an important area of study in the field of reprogramming.
Taken together, our study demonstrates that different reprogramming paradigms have the greatest
effect early in the process during the period of variable latency. Once pluripotency gene expression is
initiated, cells from all conditions follow a similar path to the pluripotent state as long as OSKM
expression is maintained. The establishment and maintenance of factor expression is a critical challenge
in monocistronic reprogramming as not all cells receive the full OSKM cocktail, nor do they maintain
their expression throughout the process in all cells. This is a key advantage of the polycistronic method
which ensures delivery of all four factors on a single construct. Our ability to make these conclusions
relies on the single-cell resolution of our analysis and the comparison between multiple reprogramming
conditions and demonstrates the need for rigorous comparison between protocols in order to determine
the effect of procedural variables on the reprogramming process.
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Chapter 4 Protein-Level Analysis of Human Reprogramming
4.1 Introduction
Reprogramming of adult somatic cells to a pluripotent embryonic-like state can be achieved
through overexpression of the four Yamanaka factors OCT4, SOX2, KLF4 and c-MYC and has been
successfully performed in both human and mouse 2,160. The development of human reprogramming in
particular represents a promising means to obtain patient-matched stem cells for therapeutic purposes and
for the modeling of disease states where the cells of interest are not readily accessible such as
Alzheimer’s and Parkinson’s disease. The great potential of this technique is limited however, by the low
efficiency of the process as well as the variability in the quality and differentiation potential of the
resulting iPSCs46,118,119. This has spurred a flurry of research in recent years to define the molecular
changes occurring as cells acquire a pluripotent phenotype with the goal of increasing the efficiency and
reproducibility of the process.
Many efforts to understand the reprogramming process have focused on transcriptional dynamics
both in bulk samples as well as in single cells 9,38,56,149. This work from our group and others has resulted
in a two phase model of reprogramming whereby the expression of transcripts early in the process is
loosely ordered and probabilistic, with genes behaving independently of one another. Late in the process
mRNA expression shows increased dependency and coordination, characteristic of a gene regulatory
network (GRN) that stabilizes cells in the pluripotent state. It is thought that the early probabilistic
expression of mRNAs is a rate-limiting step in reprogramming as this phase is protracted and only a
minority of cells progress past this point in the process. In addition, compounds that increase the rate and
efficiency of reprogramming result in greater coordination between transcripts, suggesting a more rapid
and robust activation of the pluripotency GRN facilitates reprogramming161.
The independent behavior of transcripts during the probabilistic phase of reprogramming is often
attributed to locus-specific epigenetic barriers that prevent the activation of individual loci despite the
expression of other members of the GRN and indeed, the rate limiting effects of the epigenetic landscape
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on reprogramming are well established7,9,63,65,68. However, the expression of members of the pluripotent
GRN is largely based on mRNA expression analysis and it is unclear whether these transcripts are
translated into protein, which is requisite to exert their function. At the time this project was initiated,
very little was known about protein expression during the course of reprogramming. Reprogramming
systems in mouse utilizing GFP reporters for Nanog and Oct4 demonstrated that expression of these
proteins is a late event in the process, however detection of these mRNAs occurs as early as Day 4 of
reprogramming50,51,113,149,162. In addition, we and others had observed that two surface markers commonly
used to enrich for reprogramming intermediates, SSEA-4 and TRA-1-60 are expressed in a dependent
manner (i.e. SSEA-4 is always activated before TRA-1-60). This raised the question of whether protein
expression is delayed compared with mRNA expression and if once expressed, proteins exhibit more
coordinated and dependent behavior than their cognate transcripts.
In the year since this project began, three groups have performed protein expression analysis on
mouse cells during reprogramming58,59. Zunder et. al. used mass cytometry to examine the expression of
37 proteins in secondary reprogramming mouse fibroblasts and were able to define a number of
intermediate states of reprogramming that they present as evidence for reprogramming being more
ordered at the protein level58,59. However, it is clear from their data that cells exist in a continuum between
these states and no rigorous analysis of correlation or dependency between the proteins was performed.
In addition, the mass cytometry data stands on its own and is not directly compared to the expression of
the corresponding mRNAs. In two separate studies, Benevento et. al. and Hansson et al. performed a
more direct comparison of mRNA and protein using LC/MS-MS to profile the entire proteome in bulk
reprogramming samples at different time points while collecting mRNA-seq data from the same
experiment in parallel84,85. These data demonstrate that proteins involved in the same process or that exist
is multi-subunit complexes are highly co-regulated while those involved in opposing processes exhibit an
inverse expression pattern. Interestingly however, when these proteins are compared with their
corresponding mRNA transcripts, they only exhibit strong correlations early in the process, with a greater
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discordance between the two late in reprogramming. Taken together, these studies provide strong
evidence that post-transcriptional mechanisms exist as cells approach pluripotency and may indeed be a
key step for generating iPSCs.
Because these data were generated in the mouse system and in bulk samples, it remains unclear
how these data translate to human reprogramming and whether these observations apply to the minority
of cells undergoing productive reprogramming. To this end, we utilized CyTOF technology to profile the
expression of 37 proteins at time points throughout the reprogramming process and compared these
results with our previously generate single-cell mRNA expression data. Here we directly compare the
reprogramming trajectories of cells at the mRNA and protein level and identify genes putatively subjected
to post-transcriptional regulation. Additionally, we construct mathematical models to assess the degree of
dependency between mRNAs and proteins and provide evidence for tighter regulation at the protein level.
This dataset, while limited in scope, suggests translation of stochastic transcripts into protein may also be
rate limiting in human reprogramming and that in general, the reprogramming process is more ordered at
the protein level. This work lays the foundation for a more extensive study of mRNA and protein
expression dynamics in single human cells during reprogramming in future work.

4.2 Results
4.2.1

Experimental Design

To profile the dynamics of protein expression during reprogramming, BJ fibroblasts were
infected with polycistronic lentivirus containing the OSKM reprogramming factors. Cells were harvested
at days 4, 7, 11, 14 and 21, the same time points used in our previous mRNA analysis. We also collected
BJ fibroblasts and H9 hESCs to represent the beginning and end points of the process, respectively.
Following harvest, cells were stained with metal-labeled antibodies, barcoded and run in parallel on the
Helios™ CyTOF instrument to measure the expression of 27 proteins in ~1 million individual cells.
Barcoding allows different samples to be combined into a single staining reaction and run simultaneously
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on the CyTOF to minimize technical variation (Figure 16). These samples are then computationally demultiplexed after acquisition using the manufacturer’s software. The proteins analyzed were chosen from
our 96-gene mRNA expression panel where antibodies were available (Supplemental Table 7). Preference
was given to antibodies previously validated for use in flow cytometry to simplify their optimization for
CyTOF. Antibodies were further validated and titrated on BJ fibroblasts and H9 hESCs to confirm their
specificity and expression in the appropriate cell type. This resulted in 13 targets that could be directly
compared to the mRNA dataset. Additional targets were chosen based on the work of Zunder et al.58,59
and include the intermediate markers CD73, CD49d, CD200 and PDGFRa, as well as EpCAM, an
epithelial marker expressed in hESCs.
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4.2.2

Defining the Productive vs Alternate Reprogramming Trajectories

In order to model the expression of proteins during reprogramming it is essential to profile only
the cells undergoing productive reprogramming, as unproductive events will likely exhibit different
behavior and will confound the analysis. To determine which cells were productively reprogramming we
used the viSNE algorithm to project our data into 2 dimensions, while conserving the relationships
between cells in the original high-dimensional dataset163 (Figure 17A). Importantly, viSNE is intended for
use with non-linear data, particularly flow cytometry data, making it ideal for this application.
Examination of the viSNE projection shows a clear separation of the fibroblast and hESC groups, with a
wide range of reprogramming cells spanning these two populations. This reprogramming population is
rapidly distinguished from the fibroblast group as early as day 4, and progresses toward a hESC-like
profile at subsequent days.
The expression profiles of the reprogramming factors themselves distinguish cells that have
received the virus from those that did not, since the antibodies recognize both the endogenous and
exogenous proteins. Based on these results, there is a clear population of cells at the bottom of the graph
that robustly express all four reprogramming factors (Figure 17B, red boxes). This is expected because
the reprogramming factors are translated from a polycistronic mRNA and thus all cells that receive the
virus should express the full complement of OSKM. In contrast, a population at the top of the map
exhibits low or no expression of OSKM and is distinct from the fibroblast group, suggesting these are
cells that received but pre-maturely inactivated the virus during the reprogramming process (Figure 17B,
blue boxes). The low expression we detect in this group could reasonably be attributed to residual OSKM
proteins that have yet to be turned over in the cell.

71

72

Having identified the productive population, we sought to measure the dynamics of gene
expression as cells progress through the reprogramming process. Using the progression of cells over time
as an approximation for reprogramming progress, we gated populations (Figure 18A) and measured the
median expression of each protein in the panel. Unsupervised hierarchical clustering separates these gates
into two major groups; an early group expressing fibroblast genes and lacking pluripotency gene
expression and a late group with the inverse expression profile (Figure 18B). Within these broad
classifications there is a progressive inactivation of the fibroblast genes LUM and LCK, and progressive
activation of pluripotency genes such as EpCAM, DNMT3B and NANOG. Strikingly, several surface
markers expressed in fibroblast cells are abruptly down-regulated between the early and late groups
including CD13, CD44, CD49d and CD73.
Because the above analysis relies on temporal changes in the data, which are known to be
asynchronous between cells, we turned to a recently developed, unsupervised algorithm wanderlust,
which was developed to identify cell-state transitions from high dimensional CyTOF datasets164. Briefly,
wanderlust uses a graph-based approach to construct a k nearest neighbor graph of all the cells in the
dataset, based on their similarity (in this case, protein expression profiles). The algorithm then computes
the shortest distance from each cell to a pre-defined starting cell population (fibroblast) and a randomly
chosen waypoint cell, using nearest neighbors as steps along the path. The cells are then ordered based on
these distance measurements. This process is repeated iteratively using a randomized subset of k-nearest
neighbors until convergence, providing a robust trajectory measurement. The utility of this approach is
clear when the wanderlust trajectory is mapped onto our viSNE graph (Figure 18A). This trajectory
meanders through the viSNE space, ordering cells based on protein expression similarity in a way that
could not be achieved through manual gating and provides a continuous measure of reprogramming
progress.
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Measuring protein expression dynamics along the wanderlust trajectory reveals two key
differences between the productive and non-productive trajectories. First, the non-productive population
exhibits low expression of the proliferation marker Ki67, a marker that is progressively upregulated in the
productive reprogramming populations as cells approach the hESC state (Figure 18D, right panel). This
finding is in line with data from Zunder et. al. in mouse that identified a Ki67-null population that had
exited the cell cycle and when enriched by FACS and cultured for several days, failed to produce iPSC
colonies. Second, the non-productive population robustly expresses PDGFRa, a marker that is absent in
fibroblasts cells but activated early in the productive trajectory (Figure 18D, left panel). PDGFRa is
eventually downregulated in the productive cells as they approach the hESC state, indicating that the
alternate group initiated, but will fail to complete reprogramming. Because PDGFRa is downregulated in
the productive group late in the trajectory but remains expressed in the alternate group at all time points, it
may be useful for negative selection against cells that are refractory to reprogramming at later stages of
the process.
Fibroblast and pluripotency genes exhibit the expected patterns of up- or down-regulation along
the wanderlust trajectory but groups of genes appear to change in concert at particular points in the
process (Figure 18 E and F). This is very different from the highly variable points of
activation/inactivation observed from genes in our previous mRNA expression analysis and suggests
potentially different expression dynamics at the mRNA and protein levels.
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4.2.3

Delayed Protein Expression of Key Pluripotency Genes

In order to directly compare mRNA and protein expression dynamics we first defined a common
reprogramming trajectory between the two datasets, with the alternate trajectories removed. For the
protein dataset, we examined only SSEA4+ events, since all cells collected for mRNA analysis were
enriched for SSEA4 expression. We then used Euclidean distance to measure each cell’s similarity to both
the fibroblast and hESC groups within a given dataset such that the mRNA reprogramming trajectory is
relative to fibroblast and hESC mRNA profiles, while the protein trajectory is relative to the fibroblast
and hESC protein expression profiles (Figure 19A and B). It is clear that in both datasets there is a
continuum of cell states between the fibroblast and hESC groups, although the protein dataset is slightly
more diffuse in an orthogonal direction to the productive reprogramming axis.
We next applied our Gaussian modeling pipeline to the two datasets to assess differences in the
rate or timing of protein/mRNA expression. Because the protein expression dataset has nearly 1X105-fold
more data points than the mRNA dataset, we down-sampled and bootstrapped the CyTOF data to reduce
sampling bias. Comparing the model fits between the two datasets as a whole, we observe a slight
tightening of the distributions in the protein dataset suggesting more rapid up- or down-regulation at the
protein level, however this difference is not significant (α = 0.05) for all markers across the dataset
(Figure 19C). A similar trend exists when comparing the mean point of activation/inactivation along the
trajectory, where globally, there exists a slight delay in protein expression but again this difference is not
significant (Figure 19D). When examining individual targets, it is clear that loci such as DNMT3B,
NANOG and LUM have a significant delay in protein activation while other targets do not show an effect
(Figure 19E and F).
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4.2.4

Greater Co-Regulation of Protein than mRNA Expression

To address whether protein expression exhibits greater co-regulation than mRNA expression, we
measured the degree of correlation between markers within each of these datasets. First, we generated a
background correlation that assumes independent behavior of all the genes. We then measured the
Pearson correlations for all of the genes and subtracted the background to obtain our correlation-abovebackground measurement. Figure 20 A and B demonstrates that when looking across all targets for each
dataset, there is considerably greater correlation between proteins, compared with genes at the mRNA
level. As expected, we observe strong correlation between the reprogramming factors, as these are cotranscribed and co-translated from the polycistronic virus and the CyTOF antibodies recognize both the
endogenous and exogenous species (Figure 20C). We also observe many strong correlations for
increasing and decreasing loci in the protein dataset (Figure 20 D and E), much greater than what is
observed when compared directly with correlations from mRNA expression data (Figure 20F).
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4.3 Discussion
Years of research on the molecular mechanisms of reprogramming have yielded valuable insights
into key rate limiting steps but have been primarily focused on genomic analyses such as mRNA
expression an epigenetic modifications. Until recently, the only studies of reprogramming at the protein
level were limited to techniques such as immunohistochemistry, FACS or reporter constructs, which can
only analyze a few markers at a time. The low throughput nature of these technologies limits their ability
to identify novel protein biomarkers and to compare directly to the wealth of genomics data available. As
a result, little is known about how proteins behave during reprogramming and whether posttranscriptional mechanisms may be an additional rate-limiting step in the process.
Here we present the first single cell protein expression analysis of reprogramming in human cells
using CyTOF technology and directly compare these data with single-cell mRNA expression data. The
single cell resolution of these datasets is essential for accurately comparing their dynamics during a
highly heterogeneous and temporally asynchronous process and provides greater power to assess the coregulation of these molecules. The use of human cells is more directly relevant for therapeutic approaches
and provides a necessary point of comparison for similar studies performed in mouse to determine the
commonalities and differences between these two systems.
A major finding of this work is that of the proteins examined, the pluripotency markers NANOG
and DNMT3B are expressed significantly later in reprogramming than their mRNA transcripts. From our
previous work we know that mRNA transcripts associated with pluripotency are expressed in a
probabilistic fashion prior to being upregulated in the majority of cells by the end of the process, however
it was unclear whether these transcripts were effectively translated into protein. The delayed expression of
these markers at the protein level indicates their translation is a late event in reprogramming.
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There are several reasons why this delay in translation might occur. One possibility is that the
probabilistic expression of transcripts early in the process is ephemeral and does accumulate sufficient
mRNA to be effectively translated, or that the amount translated is below the threshold of detection. This
is unlikely to be the case however, as the expression levels of these transcripts is comparable to what is
seen in hESCs, where expression of these genes as proteins is abundant. A more plausible explanation is
the presence of miRNAs or other negative regulators of mRNA translation acting within the cell. Indeed
many miRNAs are expressed in fibroblasts and the repression of aberrant transcripts is a common means
of stabilizing cellular identity40,165–167, however it is unclear whether any of these target pluripotency
genes. Analysis of miRNA expression during reprogramming has been reported previously42,152,168 and
mining these datasets for miRNAs present in fibroblasts but downregulated in iPSCs coupled with a target
prediction algorithm such as mirPath could identify putative regulators of this phenomenon. An
alternative mechanism preventing the translation of probabilistically expressed mRNAs into protein is the
absence of appropriate RNA binding proteins to stabilize the transcript or facilitate splicing into isoforms
appropriate to the cell type. Indeed many stem-cell specific RNA binding proteins have been identified
which presumably must be reactivated during reprogramming to achieve pluripotency169. The field of
RNA biology is in its infancy however, and the role of cell-type specific RNA binding proteins is largely
unknown.
Regardless of the mechanism, delayed protein expression maybe be a rate limiting step in the
process and manipulating regulators of this phenomenon could improve reprogramming efficiency. It is
important to note that not all genes in our dataset follow this pattern and it is possible that the delay in
protein expression may be the exception, rather than the rule in reprogramming. This has been
demonstrated in proteomics analysis of mouse reprogramming where only a subset of genes, mainly those
involved in cell adhesion and cell-to-cell signaling, exhibited poor correlation between mRNA and
protein expression85. To determine how many targets exhibit this effect, a larger-scale analysis would
need to be conducted. Indeed, a major limitation of the present study is the number of targets in the panel
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that can be compared directly between the mRNA and protein datasets. When developing our panel for
CyTOF, we started with a list of 96 genes for which we had already generated single-cell mRNA
expression data. After selecting targets with reliable antibodies and validating on our own cell
populations, we were left with 13 genes from the original panel. Additional markers of interest were
chosen from the literature and brought the total number of proteins analyzed to 27, however these
additional markers could not be compared with mRNA expression data. An important future direction of
this work will be to perform single cell mRNA-seq analysis of the reprogramming process and to repeat
the CyTOF experiment using a larger panel which is currently limited by the availability of rare metal
conjugates to ~40 targets. This will provide a much larger dataset and allow for more confidence and
robust statistical power to complement the data presented here.
This work also demonstrates that greater coordination exists at the protein level when compared
with the corresponding mRNA transcripts. This finding is somewhat expected given that not all
transcripts are effectively translated into protein since the presence of the protein is typically required to
exert function, for example regulating target genes. The increased correlation between proteins however
does not directly imply that the process is more deterministic at the protein level. Simply visualizing the
reprogramming trajectory derived from the protein expression data suggests a continuum of cell states
rather than a series of discrete intermediates, however assessing the degree of deterministic behavior
between proteins/mRNAs is a hypothesis that must be explicitly tested. A simple method of measuring
determinism between genes is to compare the frequency with which one genes is activated before the
other. A completely random system with no determinism between the genes would result in a frequency
near 50%; an equal chance of either gene being activated, independently of the other. In a strictly
deterministic situation, the probability of one gene activating before the other would be much greater and
would approach 100%.
Performing this test in a pairwise manner is straight forward, however looking at a complex
system such as our reprogramming datasets, requires more sophisticated analyses. Bayesian analysis is a
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powerful tool to estimate the probability of an event (expression of gene A) given other information about
the system (expression of genes B, C, D etc.). This analysis is particularly powerful when combined with
single cell analysis because each single cell collected represents a measurement of the system, and the
confidence of the predictions increases as more information is collected. Once all of the conditional
probabilities of the system have been computed, a network diagram can be assembled to understand
which genes are deeply integrated in the system and which are peripheral. It will be important to apply
this method to both our mRNA and protein datasets to see if these networks are the same, and whether
there is a difference in the dependence or connectivity of these systems. A caveat to this analysis is the
need to reduce the continuous measurements obtained from the instrument, to a binary measure of
presence or absence of expression. Single cell gene expression data lends itself well to this technique
since cells with little/no expression lack detectable amounts of transcript and are thus have inherent zero
values. In contrast, protein expression data from the CyTOF has no absolute zero values as even cells
with no expression of a marker show some background staining. Several algorithms exist to binarize
continuous datasets such as kmeans analysis or Euclidean distance stepping, both of which have been
applied successfully to similar datasets such as microarray experiments. These analysis coupled with a
larger mRNA and protein dataset for comparison will provide useful information about how effectively
mRNAs are translated into protein during reprogramming and whether chemical or other interventions
can overcome this hurdle. In addition, the analysis of a large protein dataset holds promise to identify new
biomarkers of productive reprogramming that can be used to enrich or isolate cells with increased
potential to become iPSCs.

Chapter 5 Discussion and Future Directions
5.1 Discussion
The ability to reprogram somatic cells to pluripotent iPSCs was first demonstrated in 2006 and
shows incredible promise as an autologous source of cells for transplantation and to model human
diseases in vitro. The low efficiency of the process and heterogeneity of the resulting iPSCs however, has
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limited the translation of this technique to a clinical setting. This led our group and many others to study
the mechanisms governing the reprogramming process to identify rate-limiting factors and biomarkers of
productive reprogramming.
During the time this work was conducted the field of iPSC research progressed at a dizzying rate
and many reports were published defining the molecular events preceding the acquisition of pluripotency.
Many of these early studies profiled cell populations in bulk, but in recent years single cell analysis has
been used to effectively describe the dynamics of reprogramming. Our group was the first to report single
cell transcript analysis in human reprogramming and to our knowledge, are also the first to measure
protein expression in human reprogramming as well. Through the measurement of 96 mRNAs and 27
proteins (in separate studies) we mapped the progression of cells through the reprogramming process.
Using mathematical models to describe the behavior of these molecules, we demonstrate that gene
expression dynamics are ordered yet probabilistic, reconciling previous ordered and stochastic models of
the reprogramming process. We also identify an alternate reprogramming trajectory of cells moving away
from a fibroblast state but not towards pluripotency. Because cells on this trajectory fail to express many
of the markers in our panel their exact molecular signature is unclear, however we confirm these cells are
viable and lack detection of pro-apoptotic markers.
We have also used our experimental pipeline to profile mRNA expression using different
methods of reprogramming. At a time when many methods have been used to reprogram a variety of cell
types, it is important to understand how and if variations in the technique impact the way in which cells
achieve pluripotency. By comparing two delivery methods of the OSKM factors, we show that
polycistronic reprogramming is more efficient than monocistronic reprogramming and that this is due at
least in part to premature inactivation of the reprogramming factors in the monocistronic condition. This
phenomenon also results in the alternate trajectory mentioned previously, which is present in the
monocistronic but not polycistronic dataset. In a separate experiment reprogramming BJ and MRC-5
fibroblasts with polycistronic virus, we find that the more efficient BJ cell type activates pluripotency
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genes earlier in the trajectory however, the order of gene activation remains the same. This suggest a
common reprogramming trajectory between these two cell types despite differences in efficiency.
Outside the context of reprogramming, this body of work demonstrates the power of single cell
analysis and mathematical modeling to dissect complex biological processes and gain insights not
possible at the bulk-population level. Processes such as embryonic development and cell signaling exhibit
temporal asynchrony and differential response between individual members of the population and are
amenable to the methods presented here. By taking many molecular measurements (ie gene or protein
expression) of each cell, we determine the relationship between cells, create a map of the process
independent of time and determine a parsimonious trajectory along which to model the behavior of
individual genes or proteins. This approach has since been applied by other groups164,170 and is quickly
becoming a common tool for analyzing complex systems.

5.2 Future Directions
The findings presented here represent a first step in the analysis of human reprogramming at the
single cell level and provide a framework to dissect the dynamics of the reprogramming process under
different conditions. In this work, we employed the most common reprogramming methods to establish a
“baseline” reprogramming trajectory in a relevant and widely applicable system. This same analysis
however, can and should be expanded to a variety of reprogramming systems. One approach would be to
determine the targets of small molecule compounds known to enhance the efficiency of the process. Many
small molecules such as chromatin modifying compounds (TSA, VPA,5-Aza etc.), have known targets,
while others such as OAC1, a compound identified in a screen for OCT4 activating agents, have no
known mechanism of action71. A direct comparison of reprogramming with and without these molecules
at the single cell level combined with our modeling technique is likely to reveal how these molecules
enhance reprogramming efficiency and could help identify novel barriers to reprogramming. Importantly,
single-cell mRNA-seq is quickly becoming a trivial technique and applying this technology to the
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reprogramming paradigm avoids the barriers associated with selecting a panel with a limited number of
targets.
One important finding of this work is the independent behavior of individual loci during the
stochastic phase of reprogramming, which suggests a local property of the gene governs its activity. In
line with this conclusion, the epigenetic state of pluripotency loci is known to influence the order and
timing of their activation. This implies that cell types with known differences in their epigenetic profiles
should exhibit different gene expression dynamics during reprogramming, however this hypothesis has
not been explicitly tested. We find a common reprogramming trajectory between BJ foreskin and MRC-5
lung fibroblasts, however the similarity of their epigenetic profiles is unclear and little epigenetic
profiling has been performed on MRC-5 cells. A more rigorous test of the hypothesis would be performed
in many divergent cell types by single-cell mRNA-seq.
The ENCODE project has performed ChIP-seq on dozens of commonly reprogrammed cell types,
five of which were performed by the same lab and have perfectly overlapping datasets171. These cell types
which include Human Skeletal Muscle Myoblasts (HSMM), Human Umbilical Vein Endothelial Cells
(HUVEC), Human Mammary Epithelial Cells (HMEC), Normmal Human Epidermal Karatinocytes
(NHEK) and Normal Human Lung Fibroblasts (NHLF) have been profiled for 12 different epigenetic
modifications, many of which have established roles in reprogramming. These cell types and their
accompanying epigenetic data represent a perfect system to assess whether variations in chromatin state
impact reprogramming gene expression dynamics and whether this contributes to differences in efficiency
between cell types. For example, cell types such as HSMM that have a largely repressive epigenetic
environment may take longer to activate certain pluripotency loci and thus may reprogram at lower
efficiency. In contrast, we would expect the opposite effect in HUVEC cells which have greater
developmental plasticity and thus a more permissive epigenetic environment. These cell-type level effects
would likely result from the facilitated or impaired activation of individual pluripotency loci in different
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cell types. Identification of novel loci whose activation/repression impacts reprogramming efficiency
would also be an important goal of future work.
The protein expression analysis presented in Chapter 4 provides exciting preliminary findings that
translation of stochastic transcripts into protein may be a rate limiting step in reprogramming and that the
process as a whole may be better coordinated at the protein level. This analysis however relies on too few
markers to definitively make this conclusion and several follow-up studies are necessary. First, a more
comprehensive CyTOF experiment must be performed where there is greater overlap between the mRNA
and protein expression datasets. This could be facilitated by mRNA-seq analysis of the reprogramming
process to obtain data for the whole transcriptome. From this data a large panel of targets could be
selected that are expressed/repressed at different points along the reprogramming trajectory. Starting with
a large set of markers will ensure that a sufficient number of protein targets will remain after quality
control and validation of the antibodies. With both the mRNA and protein data in hand, the degree of
determinism in the system can be inferred by Bayesian methods and our modeling approach can be used
to compare expression dynamics.
Genes or proteins that appear dependent can also be validated by orthogonal experiments, such as
those used by Buganim et. al. to validate their hierarchical model of the reprogramming process. This
method uses single molecule Fluorescent In Situ Hybridization (smFISH) to label target mRNAs coupled
with flow cytometry to measure the frequency with which one gene’s expression precedes another in
thousands of individual cells. When coupled with antibody staining, this technique could also be used to
visualize instances where the translation of an mRNA appears delayed, as observed for NANOG and
DNMT3B in our existing dataset. Furthermore, smFISH can be combined with fluorescence microscopy
to provide an absolute quantification of mRNA transcripts to determine whether translation of mRNAs
into protein is subject to a threshold effect, or whether other post-transcriptional mechanisms are
involved.
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At a time when most reprogramming studies are performed in bulk populations of mouse cells,
our profiling individual human cells undergoing reprogramming at the mRNA and protein levels
represents an important contribution to the field. In addition, the mathematical modeling approach
presented here can be used for future studies to interrogate the reprogramming process or other complex
biological processes at the single cell level. Here we provide a powerful framework for similar analyses
that will be required as the feasibility of, and necessity for, these experiments increase in the years to
come.

Chapter 6 Materials and Methods
6.1 Production of Monocistronic OSKM Retrovirus
Retroviral vectors (pMIG) containing OCT4, SOX2, KLF4, c-MYC (OSKM) along with helper
plasmids (VSV-G and Gag-pol) were obtained from I.H.Park (Yale University, New Haven, CT). To
generate viral particles, individual retroviral vectors were co-transfected with VSV-G and Gag-pol into
293T cells seeded at 2 x 106 cells per 10-cm2 using FuGENE 6 transfection reagent (Roche Applied
Science). After 72-hour induction, supernatants were collected, filtered through 0.45µm filter and
concentrated using Vivaspin 300,000 MWCO PES filter columns (Sartorius). Viral titer was determined
using FACS analysis for GFP expression (encoded in the pMIG vector). An MOI of 5 was used for all
experiments.

6.2 Production of Polycistronic OSKM Lentivirus
Simultaneous delivery of the four reprogramming factors OCT4, SOX2,KLF4 and c-MYC was
achieved using the STEMCCA-LoxP polycistronic lentiviral vector, a generous gift from Dr. Gustavo
Mustolovsky (U. Mass Boston Medical School). Virus was produced by cotransfection of STEMCCALoxP along with helper plasmids VSV-G, Gag-pol, Rev and TAT into 293T cells in 5 x 10cm2 dishes
using Xtreme-GENE9 transfection reagent. 72hrs post-transfection, supernatant was harvested and
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concentrated to 1mL using Vivaspin 300,000 MWCO PES filter columns (Sartorius), and 100ul of the
concentrated virions were used for each reprogramming experiment.

6.3 Construction of 3-Factor Reprogramming Lentiviruses
The 3-factor polycistronic vectors were constructed by modifying STEMCCA-LoxP as follows.
First, we removed either the OCT4-F2A-KLF4 or SOX2-E2A-cMYC cassette from the STEMCAA-LoxP
vector using the NotI/BamHI and NdeI/BsaBI sites, respectively. The deleted cassettes were then replaced
with one of the two original cDNAs to generate a 3-factor-containing polycistronic vector. The individual
human cDNAs encoding the four reprogramming factors were amplified from the STEMCCA-LoxP
vector using following primers: OCT4 NotI Poly F (5’-GCGGCCGCATGGCGGGACACCTGGCTTC3’); OCT4 BamHI Poly R (5’-GGATCCTCAGTTTGAATGCATGGGAGAG-3’); KLF4 NotI Poly F (5’GCGGCCGCATGGCTGTCAGCGACGCGCTG-3’); KLF4 BamHI Poly R (5’GGATCCTTAAAAATGCCTCTTCATGTG-3’); Sox2 NdeI Poly F (5’CATATGATGTACAACATGATGGAGACGG-3’); Sox2 BsaB1 Poly R (5’GATCCTAATCCTATGTGTGAGAGGGGCAGTGTG-3’); c-Myc NdeI Poly F (5’CATATGATGCCCCTCAACGTTAGCTTCACC-3’); c-Myc BsaB1 Poly R (5’GATCCTAATCTTACGCACAAGAGTTCCGTAGCTG-3’).

6.4 Cell culture and Fibroblast Reprogramming
MRC-5 human fetal lung fibroblasts were obtained from I.H. Park (Yale University, New haven,
CT) at passage 8 and BJ human foreskin fibroblasts were purchased from Global Stem (GSC-3002) at
passage 6. No cells beyond passage 10 were used for reprogramming. Briefly, fibroblast cells were
expanded in human fibroblast (hFib) media (DMEM (Gibco), 10% FBS (Milipore), 1% L-glutamine
(Gibco) and 1X Penn-Strep (Gibco)). One day prior to infection, 1 x 105 MRC-5 fibroblasts were seeded
into one well of a 6-well dish containing hFib media. The next day, cells were incubated in RI media
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(MEM alpha (Mediatech) and 10% FBS (Millipore)) containing 5ug/mL protamine sulfate (Sigma) and
OSKM virions for 24hrs followed by replacement with fresh RI media. Cells were cultured for 72hrs
post-infection and passaged to 10cm2 dishes pre-seeded with 7.5 x 105 inactivated feeders in hESC media
supplemented with 10uM ROCK inhibitor (Y-27632, Calbiochem). Cells were split 1:2 for all
monocistronic experiments and 1:3, 1:10, 1:20 and 1:30 for day 7, 11, 14 and 21 polycistronic
reprogramming, respectively. After passaging, fresh hESC media was added daily until the end of the
experiment. H9 human embryonic stem cells (WiCell) were maintained either on MEFs in hESC media
(DMEM F-12 (Gibco), 20% Knockout-Serum Replacement (Gibco), 1% L-Glutamine (Gibco), 1% NonEssential Amino Acids (Gibco), 5µM β-mercaptoethanol (Gibco), and 2ng/mL b-FGF), or feeder-free on
matrigel coated plates with mTesr-1 media following the manufacturer’s instructions. hESCs were
passaged as single cells using hES Cloning Recovery Reagent (Stemgent) to enhance clonal survival.

6.5 Antibody Staining and FACS Sorting of Reprogramming Cells
Reprogramming fibroblast cells were harvested with 1mL Accumax (Millipore) per well (6-well
dish) for 10 minutes at 37°C. Cells were pelleted, washed with PBS (Gibco) and wash buffer (2% FBS in
HBSS (Invitrogen)), and resuspended in wash buffer. Cells were then stained for 30min using αSSEA-4
(Biolegend, Cat# 330405) αTRA-1-60 (Biolegend, Cat# 330605) and αMEF (Miltenyi, 130-102-900)
antibodies, washed 3 times and resuspended in FACS buffer (1% FBS in PBS). For FACS, cells were
live/dead stained and gated on GFP (for monocistronic reprogramming) and appropriate surface markers
as indicated and single cells sorted into 96 well PCR plates. All FACS was performed using a BD
Bioscience FACS Aria II.

6.6 AP Staining and Surface Marker Quantification
Alkaline phosphatase staining was performed in 6-well plates using the alkaline phosphatase
detection kit (Millipore) per the manufacturer's instructions. Plates were images in bright field on an
Olympus SZ61 dissecting microscope and colony number and total area were counted using ImageJ. To
accurately quantify the percentage of SSEA4+ and TRA-1-60+ cells from each condition, we stained
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with biotinylated α-SSEA4 (Biolegend, 330404) or α-TRA-1-60 (Biolegend,330604) primary, followed
by Brilliant Violet-421 secondary (Biolegend 405226) and APC α-MEF (Miltenyi) at reprogramming day
14 and 21. All experiments above were performed in biological triplicate.

6.7 Quality Control and Single Cell qRT-PCR
Single cell qRT-PCR was performed as previously described 126. Single cells were sorted by
FACS into lysis solution (5% NP-40, 1000U RNasin plus (Promega, PRN2615)) and denatured by
incubating at 70°C for 10 minutes and then cooled to 4°C. Cells were then reverse transcribed with
MMLV (Promega, PR-M1705) and pre-amplified with TAKARA PCR Master Mix (TAKR004A) using
gene specific primers (0.25X pooled TaqMan assays). qPCR was performed either using TaqMan
chemistry in 384 well plates on an ABI 7900HT Fast Real-Time system, or in 96.96 Dynamic Arrays on
the BioMark-HD® system (Fluidigm). Average cycle threshold (Ct) values obtained from qPCR reactions
were normalized to GAPDH (∆Ct), and inverted by taking the (40 – ∆Ct) value. To reduce technical error
and ensure robust sample quality, all cells with a GAPDH Ct value of 25 or greater were excluded from
further analysis. TaqMan assays for endogenous OCT4, SOX2, KLF4 and c-MYC were directed against
the 3’-UTR region of the transcript, which is distinct from the synthetic UTRs incorporated in the
monocistronic OSKM transgenes, conferring their specificity to the endogenous transcripts. To test for
the presence of the viral transgenes in monocistronic reprogramming, primers targeting the synthetic
O,S,K and M UTRs were used for RT, Pre-Amp and analysis by SYBR green qPCR on an ABI 7900HT.
These primers are listed in (Supp)

6.8 Marker Panel Selection
Genes selected for inclusion in our 96 marker panel were chosen based on several criteria. For
pluripotency and chromatin modifier genes we selected those whose role in the establishment or
maintenance of the pluripotent state was well documented and experimentally validated. This decision
was further informed using the dataset of Dowell et. al. 172 which assigns a self-renewal score to genes
based on their integration in the pluripotency gene regulatory network (as determined by direct binding of
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O, S, K and/or M) as well as their degree of co-expression with well-established pluripotency genes.
Fibroblast genes were selected based on their expression in fibroblasts and absence from hESCs as
determined in 128,173.

6.9 Data Analysis from Chapter 2
6.9.1

Mapping the Reprogramming Trajectory

The Euclidean reprogramming trajectory was determined by reducing gene expression to
0(undetected) and 1(detected, Ct < 40) and calculating the average Euclidean distance for each cell to the
FIB and PLURI groups, ignoring self-comparisons. Similarity was computed for each group distance by
taking the ratio of the distance between FIB and PLURI minus each cell’s distance to the group in
question, over the distance between FIB and PLURI minus the average distance of that group to itself.
The average of the similarity to PLURI and the complement of the similarity to FIB was taken as an
estimate of the progression of each cell along the reprogramming trajectory. Distance off of the trajectory
was taken as the Euclidean distance from the FIB and PLURI similarities to the trajectory value.

6.9.2

Self-Organizing Map Analysis

PCA-based SOM analysis was performed in JMP, Version 10 (a SAS product)174 using a 5-by-1
matrix and visualizing on a biplot (PC1 vs PC2). Cells within the “Alt” group were considered to be
outliers (as described above) and were excluded from subsequent analysis, unless otherwise indicated.

6.9.3

Hierarchical Clustering

Hierarchical clustering was also performed in JMP, using Ward’s method with no
standardization, on (40-∆CT) values. Coverage ellipses on the Euclidian distance graphs represent 90%
coverage of the data points from the group indicated. For correlation analysis Pearson’s correlation
coefficients within a defined SOM grouping were taken for the entire 48x48 matrix of genes analyzed in
this study. Network graphs were constructed in Cytoscape using a force-directed layout derived from the
top 100 Pearson correlations between all of the cells, excluding outliers, in our analysis (n = 117).
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6.9.4

Model Generation

To generate accurate models, the data was first interpolated to generate a high resolution training
set. The entire sample population was included, except for outliers considered as the cells with the highest
distance off of the trajectory (10%, N=17). The training data represented the percentage of cells
expressing a gene at any point along the PLURI trajectory, and was measured by uniformly placing
overlapping bins of fixed width across the range and directly counting the number of cells expressing
each gene. Models were generated to then predict the percentage expressing at any trajectory location.
‘Uniform’ models were generated by assigning a ‘Baseline’ value at the start of the trajectory (=0), and
fixing a slope such that a straight line passed from the ‘Baseline’ to the value at the end of the trajectory
(=1). ‘Normal’ models were then fit to this data using the ‘optim’ function in R, attempting to minimize
the mean squared error, using the constraint, StdDev ≤ 3 / 16 and the following form:

dNormal (t ) = Baseline + ∑i =1 Scale i * NormalCDF (t , Meani , StdDevi )
d

In order to verify model quality and compare fitting between different models, AICc was calculated and a
bootstrapping test was performed. AICc was calculated by:

AICc = n ln MSE + 2k +

2k (k + 1)
n − k − 1'

where n is the effective number of sample points present in the original data, k is the number of free
model parameters, and MSE is the mean squared error from the model prediction to the training data.
Bootstrapping was performed by repeatedly simulating the training data but using only n bins and
randomly resampling a fixed number of cells from each bin’s range. The error between the model
prediction and the resampled data was compared to the expected error using an F-test to predict if the
error induced by lack-of-fit exceeded the pure error of the data by a significant level, and this was tracked
as a percentage of all tests done against the model.
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6.9.5

Correlation Analysis

First, simulated populations of an equal size were generated by sampling a set of points along the
reprogramming progression axis such that they matched the distribution of values in the original dataset.
For each sampling point, representative of a single simulated cell, each gene was set to detected or
undetected independently, using the frequency curves generated from our Gaussian model. Pearson
correlation coefficients were then computed for this reference population, and averaged over repeated
runs (n=1000000). Differences in correlation between this background dataset and those calculated for
our observed data were then tested for significance using the ‘r.test’ function of the R package ‘psych’.

6.10

Data Analysis and Modeling from Chapter 3

qPCR data from the Biomark was binarized such that detected genes (Ct<35) and undetected
genes were converted to 0 and 1 values, respectively. This dataset was then used for all subsequent
analysis in R v3.0.1. We then developed a modeling pipeline to describe the expression changes occurring
during reprogramming. First, we use PCA to reduce the data to two dimensions (PC1 and PC2) and we fit
a polynomial regression curve to the data and define the reprogramming trajectory. We then project each
cell to a point on the curve based on the shortest distance, providing a value for each call along the
trajectory. The trajectory values are then scaled between 0 (fibroblast) and 1 (hESC) for easier
interpretation. To model expression of each gene, we use the binary data and reprogramming trajectory to
fit a logistic regression that describes the probability of detection as reprogramming progresses.
Confidence intervals were created by bootstrapping the logistic fitting procedure 100 times and sampling
with replacement to ensure robustness of the method.

6.11

Cell Death Analysis

To evaluate the degree of cell death due to inactivation of reprogramming factors, BJ fibroblast
cells were reprogrammed using both polycistronic and 3-factor reprogramming vectors and cells were
analyzed at day 14 and day 21 in triplicate. Cells were stained either with propidium iodide or α-cleaved
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Caspase-3 (Cell Signaling, 9664P) to measure live/dead and apoptosis, respectively. All staining was
performed at the manufacturer's recommended dilution and measured on a BD FACSCalibur instrument.

6.12

Collection of Cells for CyTOF

For CyTOF, we collected reprogramming cells at days 4, 7, 11, 14 and 21 as well as BJ
fibroblasts and H9 hESCs. In order to minimize technical variation, reprogramming was initiated on
different days and all time points were collected and processed in parallel. On the day of collection cells
were harvested with Accumax reagent and stained with IdU (Fluidigm, 201127) and Cisplatin (Fluidigm,
201064) following the manufacturer’s protocol. A surface antibody cocktail was prepared by combining
all surface markers in our panel in 100ul MaxPar Cell Staining Buffer (Fluidigm, 201068).
Concentrations used for each antibody can be found in Supplemental Table 7. 3X106 cells from each time
point were incubated in the antibody cocktail for 30min at 4C, then fixed and permeabilized using the
MaxPar Nuclear Antigen Staining Buffer (Fluidigm, 201063) according to the manufacturer’s
instructions. Cells were then barcoded using the Cell-ID 20-plex Pd Barcoding Kit (Fluidigm, 201060),
combined into a single tube and stained with a cytoplasmic/nuclear antibody cocktail (100ul volume)
following the Fluidigm Nuclear Antigen Staining Protocol. Nuclear staining and CyTOF data acquisition
were performed by Fluidigm Sciences Inc (San Francisco, CA).

6.13

Data Analysis for Chapter 4

Visualization of the CyTOF dataset by viSNE and gating of cell populations was performed in
Cytobank (www.cytobank.org). Hierarchical clustering, correlation analysis and modeling were
performed as descried above with the exception that CyTOF dataset was downsampled to the same
number and per-sample representation of cells and bootstrapped 100 times to avoid biases when
comparing the two datasets. The results of the correlation analysis and model fits plot the average of these
bootstrapped runs.
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6.16

Authored Publications
6.16.1 Single Cell Analysis Reveals the Stochastic Phase of Reprogramming
to Pluripotency is an Ordered Probabilistic Process

Chung, K.-M., Kolling, F. W., Gajdosik, M. D., Burger, S., Russell, A. C., Nelson, C. E. Single
cell analysis reveals the stochastic phase of reprogramming to pluripotency is an ordered probabilistic
process. PloS One, 9(4), e95304. (2014)
Abstract: Despite years of research, the reprogramming of human somatic cells to pluripotency
remains a slow, inefficient process, and a detailed mechanistic understanding of reprogramming remains
elusive. Current models suggest reprogramming to pluripotency occurs in two-phases: a prolonged
stochastic phase followed by a rapid deterministic phase. In this paradigm, the early stochastic phase is
marked by the random and gradual expression of pluripotency genes and is thought to be a major ratelimiting step in the successful generation of induced Pluripotent Stem Cells (iPSCs). Recent evidence
suggests that the epigenetic landscape of the somatic cell is gradually reset during a period known as the
stochastic phase, but it is known neither how this occurs nor what rate-limiting steps control progress
through the stochastic phase. A precise understanding of gene expression dynamics in the stochastic
phase is required in order to answer these questions. Moreover, a precise model of this complex process
will enable the measurement and mechanistic dissection of treatments that enhance the rate or efficiency
of reprogramming to pluripotency. Here we use single-cell transcript profiling, FACS and mathematical
modeling to show that the stochastic phase is an ordered probabilistic process with independent genespecific dynamics. We also show that partially reprogrammed cells infected with OSKM follow two
trajectories: a productive trajectory toward increasingly ESC-like expression profiles or an alternative
trajectory leading away from both the fibroblast and ESC state. These two pathways are distinguished by
the coordinated expression of a small group of chromatin modifiers in the productive trajectory,
supporting the notion that chromatin remodeling is essential for successful reprogramming. These are the
first results to show that the stochastic phase of reprogramming in human fibroblasts is an ordered,
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probabilistic process with gene-specific dynamics and to provide a precise mathematical framework
describing the dynamics of pluripotency gene expression during reprogramming by OSKM.
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6.16.2 Development of intestinal organoids as tissue surrogates: Cell
composition and the Epigenetic control of differentiation
Cao, L., Kuratnik, A., Xu, W., Gibson, J. D., Kolling, F., Falcone, E. R., Ammar, M., Van Heyst,
M.D., Wright, D.L., Nelson, C.E., Giardina, C. Development of intestinal organoids as tissue surrogates:
Cell composition and the Epigenetic control of differentiation. Molecular Carcinogenesis, 202(April
2013), 189–202. http://doi.org/10.1002/mc.22089 (2013)
Abstract: Intestinal organoids are multicellular crypt-like structures that can be derived from
adult intestinal stem cells (ISCs), embryonic stem cells (ESCs) or induced pluripotent stem cells (IPSCs).
Here we show that intestinal organoids generated from mouse ESCs were enriched in ISCs and early
progenitors. Treatment of these organoids with a γ-secretase inhibitor increased Math1 and decreased
Hes1 expression, indicating Notch signaling regulates ISC differentiation in these organoids. Lgr5 and
Tert positive ISCs constituted approximately 10% and 20% of the organoids. As found in native tissue,
Lgr5 and Tert expressing cells resolved into two discreet populations, which were stable over time.
Intestinal organoids derived from cancer-prone Apc(Min/+) mice showed similar numbers of ISCs, but
had reduced Math1 expression, indicating a suppressed secretory cell differentiation potential (as found in
intestinal tissue). Apc(Min/+) organoids were used to screen epigenetically active compounds for those
that increased Math1 expression and organoid differentiation (including HDAC inhibitors, Sirtuin (SIRT)
modulators and methyltransferase inhibitors). Broad-spectrum HDAC inhibitors increased both Math1
and Muc2 expression, indicating an ability to promote the suppressed secretory cell differentiation
pathway. Other epigenetic compounds had a diverse impact on cell differentiation, with a strong negative
correlation between those that activated the secretory marker Muc2 and those that activated the absorptive
cell marker Fabp2. These data show that ESC-derived intestinal organoids can be derived in large
numbers, contain distinct ISC types and can be used to screen for agents that promote cell differentiation
through different lineage pathways.
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6.16.3 pH dependence of amylin fibrillization
Jha, S., Snell, J. M., Sheftic, S. R., Patil, S. M., Daniels, S. B., Kolling, F. W., & Alexandrescu,
A. T. pH dependence of amylin fibrillization. Biochemistry, 53(2), 300–10.
http://doi.org/10.1021/bi401164k (2014)
Abstract: In type 2 diabetics, the hormone amylin misfolds into amyloid plaques implicated in
the destruction of the pancreatic β-cells that make insulin and amylin. The aggregative misfolding of
amylin is pH-dependent, and exposure of the hormone to acidic and basic environments could be
physiologically important. Amylin has two ionizable residues between pH 3 and 9: the α-amino group and
His18. Our approach to measuring the pKa values for these sites has been to look at the pH dependence of
fibrillization in amylin variants that have only one of the two groups. The α-amino group at the
unstructured N-terminus of amylin has a pKa near 8.0, similar to the value in random coil models. By
contrast, His18, which is involved in the intermolecular β-sheet structure of the fibrils, has a pKa that is
lowered to 5.0 in the fibrils compared to the random coil value of 6.5. The lowered pKa of His18 is due to
the hydrophobic environment of the residue, and electrostatic repulsion between positively charged His18
residues on neighboring amylin molecules in the fibril. His18 acts as an electrostatic switch inhibiting
fibrillization in its charged state. The presence of a charged side chain at position 18 also affects fibril
morphology and lowers amylin cytotoxicity toward a MIN6 mouse model of pancreatic β-cells. In
addition to the two expected pKa values, we detected an apparent pKa of ~4.0 for the amylin-derived
peptide NAc-SNNFGAILSS-NH2, which has no titratable groups. This pKa is due to the pH-induced
ionization of the dye thioflavin T. By using alternative methods to follow fibrillization such as the dye
Nile Red or turbidimetry, we were able to distinguish between the titration of the dye and groups on the
peptide. Large differences in reaction kinetics were observed between the different methods at acidic pH,
because of charges on the ThT dye, which hinder fibril formation much like the charges on the protein.
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6.16.4 SCLD: a Stem Cell Lineage Database for the annotation of cell types
and developmental lineages
Hemphill, E. E., Dharia, A. P., Lee, C., Jakuba, C. M., Gibson, J. D., Kolling, F. W., & Nelson,
C. E. SCLD: a stem cell lineage database for the annotation of cell types and developmental lineages.
Nucleic Acids Research, gkq941. (2010)
Abstract: Stem cell biology has experienced explosive growth over the past decade as
researchers attempt to generate therapeutically relevant cell types in the laboratory. Recapitulation of
endogenous developmental trajectories is a dominant paradigm in the design of directed differentiation
protocols, and attempts to guide stem cell differentiation are often based explicitly on knowledge of in
vivo development. Therefore, when designing protocols, stem cell biologists rely heavily upon
information including (i) cell type-specific gene expression profiles, (ii) anatomical and developmental
relationships between cells and tissues and (iii) signals important for progression from progenitors to
target cell types. Here, we present the Stem Cell Lineage Database (SCLD) (http://scld.mcb.uconn.edu)
that aims to unify this information into a single resource where users can easily store and access
information about cell type gene expression, cell lineage maps and stem cell differentiation protocols for
both human and mouse stem cells and endogenous developmental lineages. By establishing the SCLD,
we provide scientists with a centralized location to organize access and share data, dispute and resolve
contentious relationships between cell types and within lineages, uncover discriminating cell type marker
panels and design directed differentiation protocols.
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6.16.5 Regulation of the Fanconi anemia pathway by a CUE ubiquitinbinding domain in the FANCD2 protein
Rego, M. A., Kolling, F. W., Vuono, E. A., Mauro, M., & Howlett, N. G. Regulation of the
Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Blood, 120(10),
2109–2117. (2012)
Abstract: The Fanconi anemia (FA)-BRCA pathway is critical for the repair of DNA interstrand
crosslinks (ICLs) and the maintenance of chromosome stability. A key step in FA-BRCA pathway
activation is the covalent attachment of monoubiquitin to FANCD2 and FANCI. Monoubiquitinated
FANCD2 and FANCI localize in chromatin-associated nuclear foci where they interact with several wellcharacterized DNA repair proteins. Importantly, very little is known about the structure, function, and
regulation of FANCD2. Herein, we describe the identification and characterization of a CUE (coupling of
ubiquitin conjugation to endoplasmic reticulum degradation) ubiquitin-binding domain (UBD) in
FANCD2, and demonstrate that the CUE domain mediates noncovalent binding to ubiquitin in vitro. We
show that although mutation of the CUE domain destabilizes FANCD2, the protein remains competent
for DNA damage-inducible monoubiquitination and phosphorylation. Importantly, we demonstrate that
the CUE domain is required for interaction with FANCI, retention of monoubiquitinated FANCD2, and
FANCI in chromatin, and for efficient ICL repair. Our results suggest a model by which
heterodimerization of monoubiquitinated FANCD2 and FANCI in chromatin is mediated in part through
a noncovalent interaction between the FANCD2 CUE domain and monoubiquitin covalently attached to
FANCI, and that this interaction shields monoubiquitinated FANCD2 from polyubiquitination and
proteasomal degradation.
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6.16.6 The p21Cip1/Waf1 cyclin-dependent kinase inhibitor is required for
the activation of the FA-BRCA pathway
Rego, M. A., Mauro, M., Harney, J. A., Shen, M., Kolling, F. W., & Howlett, N. G. Abstract LB102: The p21Cip1/Waf1 cyclin-dependent kinase inhibitor is required for the activation of the FA-BRCA
pathway. Cancer Research, 70(8 Supplement), LB–102. (2010)
Abstract: Fanconi anemia (FA) is a rare disease characterized by congenital defects, progressive
bone marrow failure and heightened cancer susceptibility. The FA proteins, BRCA1 and
FANCD1/BRCA2 function cooperatively in the FA-BRCA pathway to repair damaged DNA. Activation
of the FA-BRCA pathway occurs via the monoubiquitination of the FANCD2 and FANCI proteins,
targeting these proteins to discrete nuclear foci where they function in DNA repair. The cellular
regulation of FANCD2/I monoubiquitination, however, remains poorly understood. In this study, we have
examined the roles of the p53 tumor suppressor protein, as well as its downstream target, the
p21(Cip1/Waf1) cyclin-dependent kinase inhibitor, in the regulation of the activation of the FA-BRCA
pathway. We demonstrate that, in contrast to p53, p21 has a major role in the regulation of the activation
of the FA-BRCA pathway: p21 promotes S-phase and DNA damage-inducible FANCD2/I
monoubiquitination and nuclear foci formation. Several lines of evidence establish that this effect is not a
consequence of a defective G1-S checkpoint or altered cell-cycle progression in the absence of p21.
Instead, we demonstrate that p21 is required for the transcriptional repression of the USP1
deubiquitinating enzyme upon exposure to DNA-damaging agents. In the absence of p21, persistent USP1
expression precludes the DNA damage-inducible accumulation of monoubiquitinated FANCD2 and
FANCI. Consequently, p21(-/-) cells exhibit increased levels of mitomycin C-inducible complex
chromosomal aberrations and elevated γH2AX nuclear foci formation. Our results demonstrate that p21
has a critical role in the regulation of the activation of the FA-BRCA pathway and suggest a broader role
for p21 in the orchestration of DNA repair processes following exposure to DNA crosslinking agents.
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6.16.7 Functional interaction between the Fanconi Anemia D2 protein and
proliferating cell nuclear antigen (PCNA) via a conserved putative
PCNA interaction motif
Howlett, N. G., Harney, J. A., Rego, M. A., Kolling, F. W., & Glover, T. W. (2009). Functional
interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a
conserved putative PCNA interaction motif. Journal of Biological Chemistry, 284(42), 28935–

28942.
Abstract: Fanconi Anemia (FA) is a rare recessive disease characterized by congenital
abnormalities, bone marrow failure, and cancer susceptibility. The FA proteins and the familial breast
cancer susceptibility gene products, BRCA1 and FANCD1/BRCA2, function cooperatively in the FABRCA pathway to repair damaged DNA and to prevent cellular transformation. Activation of this
pathway occurs via the mono-ubiquitination of the FANCD2 protein, targeting it to nuclear foci where it
co-localizes with FANCD1/BRCA2, RAD51, and PCNA. The regulation of the mono-ubiquitination of
FANCD2, as well as its function in DNA repair remain poorly understood. In this study, we have further
characterized the interaction between the FANCD2 and PCNA proteins. We have identified a highly
conserved, putative FANCD2 PCNA interaction motif (PIP-box), and demonstrate that mutation of this
motif disrupts FANCD2-PCNA binding and precludes the mono-ubiquitination of FANCD2.
Consequently, the FANCD2 PIP-box mutant protein fails to correct the mitomycin C hypersensitivity of
FA-D2 patient cells. Our results suggest that PCNA may function as a molecular platform to facilitate the
mono-ubiquitination of FANCD2 and activation of the FA-BRCA pathway.
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6.16.8 The Fanconi anemia protein interaction network: Casting a wide net
Rego, M. A., Kolling, F. W., & Howlett, N. G. The Fanconi anemia protein interaction
network: Casting a wide net. Mutation Research/Fundamental and Molecular Mechanisms of
Mutagenesis, 668(1), 27–41. (2009)
Abstract: It has long been hypothesized that a defect in the repair of damaged DNA is central to the
etiology of Fanconi anemia (FA). Indeed, an increased sensitivity of FA patient-derived cells to the lethal
effects of various forms of DNA damaging agents was described over three decades ago [A.J. Fornace,
Jr., J.B. Little, R.R. Weichselbaum, DNA repair in a Fanconi's anemia fibroblast cell strain, Biochim.
Biophys. Acta 561 (1979) 99-109; Y. Fujiwara, M. Tatsumi, Repair of mitomycin C damage to DNA in
mammalian cells and its impairment in Fanconi's anemia cells, Biochem. Biophys. Res. Commun. 66
(1975) 592-598; A.J. Rainbow, M. Howes, Defective repair of ultraviolet- and gamma-ray-damaged DNA
in Fanconi's anaemia, Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 31 (1977) 191-195].
Furthermore, the cytological hallmark of FA, the DNA crosslink-induced radial chromosome formation,
exemplifies an innate impairment in the repair of these particularly cytotoxic DNA lesions [A.D.
Auerbach, Fanconi anemia diagnosis and the diepoxybutane (DEB) test, Exp. Hematol. 21 (1993) 731733]. Precisely defining the collective role of the FA proteins in DNA repair, however, continues to be
one of the most enigmatic and challenging questions in the FA field. The first six identified FA proteins
(A, C, E, F, G, and D2) harbored no recognizable enzymatic features, precluding association with a
specific metabolic process. Consequently, our knowledge of the role of the FA proteins in the DNA
damage response has been gleaned primarily through biochemical association studies with non-FA
proteins. Here, we provide a chronological discourse of the major FA protein interaction network
discoveries, with particular emphasis on the DNA damage response, that have defined our current
understanding of the molecular basis of FA.
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6.17

Manuscript Under Review
6.17.1 Comparison of Reprogramming Methods by Single Cell Analysis
Identifies Premature Viral Inactivation as a Barrier to Successful
Reprogramming and Reveals a Common Reprogramming Trajectory
Between Cell Types

Kolling, F. W., Chung, K.-M., Chen, K., Bar, H., Schifano, E. D., Harel, O., Mandiou, Ion I.,
Nelson, C. E. Comparison of Reprogramming Methods by Single Cell Analysis Identifies Premature
Viral Inactivation as a Barrier to Successful Reprogramming and Reveals a Common Reprogramming
Trajectory Between Cell Types. PloS One. (2015).
Abstract: Reprogramming terminally differentiated cells to a pluripotent state by exogenous expression
of the Yamanaka factors OCT4, SOX2, KLF4 and c-MYC (OSKM) has the potential to revolutionize
many aspects of modern medicine. However, despite years of research this process remains highly
inefficient and produces considerable cellular heterogeneity, problems that must be overcome before this
technique can be used clinically. In the years following the first reports of OSKM-mediated
reprogramming, several methods have been developed to reprogram cells to pluripotency in an effort to
increase the efficiency and quality of iPSC generation, including using different methods of delivering the
OSKM factors as well as the use of novel reprogramming factors. While many of these approaches have
increased the efficiency and/or rate of reprogramming, at present it is unclear how these results manifest
at the molecular level and how these various methods impact the quality and differentiation potential of
resulting iPSCs. In this study, we apply single cell transcript analysis to compare the transcriptional
dynamics underlying the acquisition of pluripotency in monocistronic and polycistronic OSKM systems.
These two delivery methods were tested in both MRC-5 and BJ fibroblasts. We demonstrate that
polycistronic viral delivery produces significantly higher reprogramming efficiencies compared with
monocistronic delivery and that this effect is due in part to premature inactivation of the individual O,S,K
or M vectors in the monocistronic method. In addition, we show that the activation of key pluripotency
loci such as NANOG, OCT4, LIN28 and DNMT3B occurs earlier in the polycistronic condition and that
these cells progress more uniformly towards pluripotency. Finally, we compare polycistronic
reprogramming between MRC-5 and BJ fibroblast cells and reveal that while the order of gene activation
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is similar between cell types; MRC-5 and BJ cells take divergent paths upon factor induction, followed by
convergence later in the reprogramming process.
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